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Dedication
While reading through survey responses, I came across one that just stopped me.
It is just a simple thing, but it was something my mom always tells me. The participant
had responded to a question, which asked them to give advice to those who will find out
they are BRCA1/2 positive in the future. She wrote: “I would tell them to breathe.
Knowledge is power and knowing is such a blessing. Many people will never know that
they will get cancer. This is such a blessing to those who can know and do something
about it.”
This response reminded me so much of something my mom would say to me.
So—I dedicate my thesis project to my mom, the lady who made me breathe and
remember the blessings I do have throughout the writing of this thesis. In addition, I
would like to dedicate this to anyone who is BRCA1/2 positive. There is so much we
could all learn from the strength and kindness of the amazing women I encountered
through the collection of this data you are about to see.
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Abstract
Objective: To examine if BRCA1/2 mutation carriers who received their positive genetic
test result by age 25 were satisfied with their decision to undergo genetic testing and with
the choices made regarding family planning, surveillance, and surgery. Methods: 72
participants recruited via social media completed a survey hosted by SurveyMonkey.com.
Sixty-three met study criteria and were asked 40 quantitative and qualitative questions
designed to assess family planning, surveillance, and surgery needs of young BRCA
carriers, which included a six question Satisfaction with Decision Scale. Results:
Regardless of age, participants were very satisfied with the decision to undergo genetic
testing. Recommendations were made for the counseling and care of BRCA1/2 mutation
carriers under age 25, which included: (1) Right Reproductive Organs, (2) Risk Reducing
Mastectomy, (3) Risk Figures, (4) Reproductive Options, and (5) Resource for Future.
Conclusions: Participants desired more clear and unbiased care and counseling, where
they felt supported. The complexity of HBOC plus the variable lives BRCA1/2 positive
emerging adults face led us to propose a core set of counseling recommendations for
young BRCA mutation carriers under age 25. Incorporating the five recommendations is
essential to achieving full patient autonomy and unbiased decision facilitation.

Keywords: cancer, oncology, BRCA1/2, genetic testing, testing satisfaction,
emerging adults
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Chapter 1: Background
1.1 BRCA1 and BRCA2 Basics
Cancer is a major health problem in many countries. In the United States, it causes one
in four deaths. In 2012, there were 229,060 new cases of breast cancer. Of these,
226,870 were females and 2,190 were males. Breast cancer was the cause of 39,920
deaths. Of these deaths, 39,510 were females and 410 were males. Ovarian cancer was
reported in 22,280 new cases and 15,500 deaths. (Siegel, Naishadham, & Jemal, 2013).
Breast and ovarian cancer are not unusual in the general population. One in
eight, or 12.5% of women will develop breast cancer over their lifetime while one to two
in one hundred, or 1-2% of women will develop ovarian cancer. The average risk for
cancer gradually increases over one’s lifetime (Petrucelli, Daly, & Feldman, 2011).
While a majority of cancers are sporadic or randomly occurring, about 10% of all breast
and ovarian cancer cases are hereditary, or passed down though families.
Individuals with hereditary cancer have a higher risk of developing cancer than
individuals in the general population. Hereditary cancer is due to germline mutations, or
genetic changes that are passed down from parent to child. Among the individuals that
fall within this hereditary breast cancer susceptibility group, 35% of cases will be due to a
mutation in the BRCA1 gene while 37% of cases will be due to a mutation in the BRCA2
gene. Among those in the hereditary ovarian cancer susceptibility group, 80% will have
a BRCA1 mutation and 15% will have a BRCA2 mutation. The remaining cases are due
to other genes or unknown causes (Clark & Domchek, 2011; Ford, et al., 1998).
1

BRCA1 and BRCA2 are the two genes that cause the genetic condition known as
Hereditary Breast and Ovarian Cancer Syndrome (HBOC). HBOC is a hereditary cancer
predisposition syndrome that is caused by mutations or changes in one of these two
genes. Each gene has two alleles, or copies. One is passed on from the father and one is
passed on from the mother. Receiving a mutated copy of one of these genes from either
parent can increase an individual’s risk for various types of cancer. In nearly all cases,
these mutations are passed down in families. Very few de novo, or randomly occurring
mutations in these genes have been reported. The incidence of de novo mutations in
either the BRCA1 or the BRCA2 gene is thus unknown.
HBOC syndrome is inherited in an autosomal dominant fashion, meaning that just
one mutated copy of the BRCA1 gene or the BRCA2 gene will cause this predisposition
that may lead to cancer. If a parent has a mutated copy, each child has a 50% risk of
inheriting the mutated copy of the gene. The highest cancer risk is for breast or ovarian
cancer, but other cancers such as pancreatic, prostate, or fallopian tube cancer can result.
A slight yet increased risk has been found for melanoma in BRCA2 carriers and for
endometrial cancer in BRCA1 carriers (Clark & Domchek, 2011; Segev et al., 2013).
The overall prevalence of BRCA1 and BRCA2 mutations in the general population
is between 1/400 and 1/800 individuals. The incidence depends on ethnicity. The
highest incidence is seen in the Ashkenazi Jewish population. The incidence is 1/40
primarily due to three common founder mutations, 187delAG and 5385insC for BRCA1
and 6174delT for BRCA2. Dutch and Icelandic populations also have a higher incidence
of BRCA1 or BRCA2 gene mutations (Petrucelli et al., 2011).
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There are differences in lifetime cancer risk for women depending on whether
they carry a mutation in the BRCA1 or the BRCA2 gene. On average, 60-70% of women
with a BRCA1 gene mutation will develop breast cancer by the age of 70, while an
average of 40% will develop ovarian cancer, which includes fallopian tube and primary
peritoneal carcinomas. For women with a BRCA2 gene mutation, an average of 45-55%
of women will develop breast cancer by age 70 while 20% will develop ovarian cancer.
Women also have an increased risk for other cancers such as pancreatic cancer or
melanoma (Clark & Domchek, 2011). The highest risk for these two types of cancer in
women is thus associated with a BRCA1 gene mutation (Petrucelli et al., 2011). Women
have up to a 10% risk of pancreatic cancer as well (Ford, et al., 1998).
Males with a BRCA2 gene mutation have up to an 8% risk of developing breast
cancer. Those with a BRCA1 mutation have up to a 1% risk (Petrucelli et al., 2011;
Shiloh, Dagan, Friedman, Blank, & Friedman, 2013). Males have up to a 2-6% risk of
gastric and pancreatic cancer, with the highest risk being for males with a BRCA2 gene
mutation. Men have a slightly increased risk for prostate cancer over that of the general
population (Shiloh et al., 2013). The age of cancer onset is similar to that of sporadic
breast cancers in the general population with BRCA2 mutations (Ford et al., 1998).
1.2 Targeting Individuals who Tested BRCA Mutation Positive as Emerging Adults
Individuals who are between the ages of 18 and 24 are in a highly transitional
period of their lives now known as emerging adulthood. Emerging adulthood, a phrase
coined in 2000 by Arnett, describes a unique demographic period that pertains to the
exploration of one’s identity through the postponement of adulthood. Young, BRCA
mutation positive individuals are potentially making major choices and decisions that will
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impact their lives for years to come. These decisions can include career, significant
other, family planning, and geographic location choices. By the late 20s, a majority of
individuals have made decisions in their lives that will have lasting consequences.
Further, when adults retrospectively considered the most crucial events in life, they
mainly cited events in this period (Arnett, 2012).
As a result of these fast-paced changes and choices, researchers have started to
examine if having a BRCA1 or BRCA2 gene mutation impacts this tumultuous time in life
(e.g. Hoskins, Werner-Lin, etc.). Individuals who fit into this emerging adulthood group
and who are from families with an identified BRCA1/2 gene mutation may base decisions
regarding normal life transitions upon a timeline of when they expect illness to occur.
Anxiety, worry, and grief regarding disease have been found to play an underlying role in
this transitional era in life when hereditary cancer is an issue (Werner-Lin, 2007).
There is much research that still needs to be done for this critical demographic
group, because the current professional medical guidelines available to young, BRCA
positive individuals suggest genetic testing be made available when they reach the age of
eighteen (Trepanier et al., 2004). However, this recommendation is based on the principle
that individuals of this age can now act as autonomous adults. Though they are able to
make informed decisions about their own risks and genetic testing, the true autonomy is
debatable. For young, high-risk individuals of this age group, autonomous decisionmaking is one of the milestones in development that may not yet be reached (Arnett,
2000). Many individuals in this age group may still live at home, at least part time, and
still be dependent on their parents or guardians for support. This support could range
from financial support to facilitating their child’s decision-making processes.

4

The major concern is that young, BRCA positive individuals may experience
greater harm and lesser benefits to their psychosocial well-being when learning about
their BRCA1/2 mutation carrier status. Compared to individuals older than 25,
individuals diagnosed with a BRCA1/2 gene mutation as emerging adults may find that
there are fewer concrete recommendations for them to utilize once they know their status.
With or without the support of their family members or other health care providers, the
decision-making processes that young, BRCA positive individuals undertake are distinct
from individuals of the same age in the general population. This age group is also unique
from all other individuals who are a part of the overall group of families with HBOC.
Young mutation carriers know they are BRCA positive by age 25, but there is little
published data on what actions to take regarding this life-changing information.
In two related studies, it was determined that complex decision making processes
evolve over time. The ability to fully understand and act on newly discovered genetic
information and to make confident, life-altering decisions is still developing in this
period. Therefore, it will be critical to have support and guidance at this point in the life
cycle to assure young, BRCA positive individuals make autonomous, informed choices
where they fully understand both the benefits and risks of knowing one’s mutation status.
This study suggested that it would be critical to have concrete goals to model decisionmaking upon, as well as resources from providers who will deliver the genetic education
and information to this age group. Support and guidance to assure young, BRCA positive
individuals are making autonomous, informed choices and fully understand the benefits
and risks of knowing one’s mutation status is key (Werner-Lin, Hoskins, Doyle, &
Greene, 2012). Specifically, these young BRCA mutation carriers report a desire for
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clearer screening guidelines and continuing support regarding their medical care over
time, as their life and needs evolve (Hoskins, Werner-Lin, & Greene, 2014).
In another study pertaining to women who are 18-24 years old, Patenaude et al.
(2013) looked at levels of concern and knowledge about hereditary cancer in young
women who have BRCA1 or BRCA2 positive mothers. They found that one third of the
daughters reported high cancer-related distress, even though they had expressed normal
levels of general distress. Knowing this genetic information about their mothers raised
concerns for their futures, especially in regards to having children. The level of
knowledge about HBOC was suboptimal with many misconceptions about their risk for
carrying a BRCA mutation. This indicated that future studies could be vital in
determining how young, BRCA positive women are coping after they undergo genetic
testing themselves and also test positive for a BRCA1 or BRCA2 gene mutation.
This study collected data from several different, industrialized countries that may
inform individuals and health providers in similarly industrialized countries. Delaying
marriage and childbearing in favor of gaining an education first is increasing among
industrialized countries. Individuals from industrialized countries in this age range may
experience comparable dilemmas. This is because emerging adulthood is not a universal
developmental period, but a stage in life seen only in cultures that postpone entry into
adult responsibilities until individuals are in their early to mid twenties (Arnett, 2000).
1.3 The Risks Faced by BRCA Mutation Carriers By Age 25
Females and males under age 25 are at a low risk to developing cancer. Even
though breast cancer is the leading cause of cancer death among women, breast cancer
does not make the top five leading causes of cancer-related deaths in women under age
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20 (Siegel et al., 2013). For young BRCA1/2 gene mutation carriers, the relative risk at
this time may seem higher. Particularly since their absolute risk or lifetime risk for
cancer is significantly higher than other women in the general population.
In actuality, young BRCA1/2 carriers have a small chance to develop an HBOC
related cancer before age 30. The risk for developing breast cancer before age 30 is
about 4.6% for women who carry a BRCA1/2 mutation (Ford et al., 1998) while the risk
for developing ovarian cancer is nearly zero (Stratton et al., 1999). Between the ages of
20 to 24, the risk is even lower. It is estimated that the incidence for BRCA1 and BRCA2
mutation carriers is .02% for breast cancer and .001% for ovarian cancer (Antoniou et al.,
2003). While these numbers are low, BRCA1 and BRCA2 mutation carriers between the
ages of 20 and 29 still have a relative risk to have breast cancer that is 5 to 20 times
higher then a woman of the same age in the general population (Clark & Domchek,
2011). For males, the risk of developing cancer is even lower. Male cancer risk typically
does not start until age 40 (Shiloh et al., 2013).
The looming lifetime risk for cancer may drive many young individuals to
undergo genetic testing earlier then some guidelines suggest (Ormondroyd et al., 2012).
This is because individuals who are 18 to 24 years in age do not yet have a fully
developed frontal lobe of their brain, leading them to have impaired judgment, morality,
and abilities to make long-term plans. This time in life is still a critical period in the
development of the human brain (Steinberg, 2005). Young mutation carriers may feel
life is now like a waiting game, or that they are a ticking cancer bomb, even though the
actual risk for developing cancer is not inevitable (Kwong & Chu, 2012). Young, BRCA
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positive individuals may act as though cancer development will be experienced in the
near future even though this is improbable (Hoskins & Warner-Lin, 2012).
While these fears may push some young carriers to consider surgical treatment or
risk-reducing drug options. Many surgeons fear that these decisions may cause regret for
young, BRCA positive individuals later in life. Surgeons may be cautious to remove
seemingly healthy breast and especially ovarian tissue from women in this young age
group due to the risks associated with these major surgeries such as pain syndromes and
body image issues, even if they do carry a genetic mutation (Kwong & Chu, 2012).
Young, BRCA positive individuals may seek advice from their primary health care
providers, surgeons, or gynecologists. Many health care providers are unlikely to be
trained to handle the sensitive nature of topics related to BRCA for this age group.
Unlike many other mutation positive individuals, young, BRCA positive individuals’
surgical decisions cannot be made quickly. This group needs support to assure that they
have considered all facets related to their decision and its potential ramifications, since
they are less likely be mature when making independent decisions and acting
autonomously (Werner-Lin, Hoskins, Doyle, & Greene, 2012).
Despite the low risks of developing cancer, young, BRCA positive individuals
may continue to face anxiety and fear once they know their carrier status. Genetic
counseling and care for young, BRCA positive individuals involve considering
psychosocial adaptation and risk management like all other patients. This group is
unique in the sense that the traditional options given to individuals, such a surgical
choices and reproductive planning, may not seem to apply at the time of genetic test
result disclosure. Reproductive issues and surgical options are related topics however.
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Thus, they may be highly appropriate subjects for young carriers to learn of in a genetic
counseling session, since they may not have begun or completed their families (Kwong &
Chu, 2012; Ormondroyd et al., 2012).
While young, BRCA positive individuals may be hesitant to learn all of this
information; basic knowledge will be key for future decisions. The ability to carefully
think ahead and plan for the future is a rare opportunity this group has, where compared
to older BRCA carriers. The sensitive and complex nature of these BRCA-related topics
as well as the likelihood that they will have an impact on each individual’s life requires
careful discussion with trained health care providers to navigate through possible issues
(Ormondroyd et al., 2012). Otherwise, there is a possibility that young, BRCA positive
individuals may experience distress regarding having genetic testing or the choices that
they have made based on their BRCA1/2 positive status.
Emerging adults in this high-risk group can be made aware of recommended
options for surveillance, chemoprevention, and prophylactic surgery. All surveillance
guidelines state that mutation positive individuals should start formal surveillance at the
age of 25 or older. Guidelines also suggest that high-risk individuals could start
screening or surveillance as many as 10 years prior to the earliest age of diagnosis in their
family. Although for some families, this age still may not fall before 25 years of age,
continuing to leave young, BRCA positive individuals without concrete options.
When reviewing core guidelines for high-risk individuals, it is clear why this
group feels worried and confused about what they should do with this knowledge
regarding their genetic make-up (Werner-Lin, Hoskins, Doyle, & Green, 2012).
Recommendations bypass this group. It is recommended that annual mammograms and
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breast MRIs should begin at the age of 25. Clinical breast exams (CBE) should be done
annually or bi-annually starting at age 25, which can include high-risk men (Berliner,
Fay, Cummings, Burnett, & Tillmanns, 2013). Men are often suggested to wait until the
age of 40 since they are at a lower overall risk for breast cancer (Shiloh et al., 2013). At
the age of 30, women can elect to have CA-125 screening and transvaginal ultrasounds to
screen for ovarian cancer, even though the utility has yet to be proven for these tools. At
age 40, colorectal cancer screening via colonoscopies and PSAs for prostate cancer
should be performed yearly (Berliner, Fay, Cummings, Burnett, & Tillmanns, 2013).
Chemoprevention may be considered, and there are several options for women.
Oral contraceptives may be recommended, and have been known to decrease the risk of
ovarian cancer up to 45-60% if used over a period of five years in high-risk women who
have a history of ovarian cancer (Berliner et al., 2013). Medications such as tamoxifen or
other chemopreventive drugs reduce the risk of developing breast cancer as well. In a
study of women who have an increased risk for breast cancer either because of family
history or because their age greater then 60, tamoxifen reduced the risk for invasive
breast cancer by 49%. It also reduced the risk for women 49 and younger by 44%
(Fisher, et al. 1998).
There are also two main risk-reducing surgical options for women. A risk
reducing bilateral mastectomy may be considered. This surgery reduces the risk of breast
cancer by at least 90%. There is no standard age for which this is recommended. In
addition, this more aggressive treatment through a surgical procedure may be more
strongly considered if the patient has limited access to knowledgeable physicians,
chemotherapeutic drugs, and surveillance equipment, such as MRI machines. A risk-
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reducing bilateral salpingo oophorectomy (BSO) can also be performed. This reduces the
risk for ovarian cancer by 80-96% and reduces the risk of breast cancer by up to 50% in
women who have not yet gone through menopause. This is because hormone levels in
young, BRCA positive women will drop following the removal of their ovaries, resulting
in a decrease in the hormones present that would fuel cancer growth. This surgery is
recommended for women between the ages of 35 to 40. This surgery will cause women
to enter early menopause. There are currently no guidelines and little data regarding
chemoprevention or prophylactic surgeries for high-risk men (Berliner et al., 2013).
Since all of these options are recommended for those ages 25 and older, young
individuals in this group may feel helpless in regard to taking control of their health. For
some, the fear of developing cancer may lead them to proceed with some of these
treatments or surgeries. For others, the concept of the waiting game may seem all too
familiar (Hoskins & Werner-Lin, 2012). No matter what path is taken, we aim to better
understand the rationale and thought processes for young, high-risk individuals though
this study. The hope is that others’ experiences will better aid the young, BRCA1/2
positive individuals of tomorrow.
1.4 Need for Targeting BRCA1/2 Positive Emerging Adults
According to guideline recommendations, this group of individuals between the
age of 18 and 24 are the youngest candidates for BRCA1 and BRCA2 testing. While
young, BRCA positive individuals have a low risk for cancer during this time in life,
BRCA mutation positive individuals still feel as though they are at high relative risk for
receiving a cancer diagnosis. They may find themselves in a dilemma as far as their risk
management. There is a significant lack of data for individuals who underwent genetic
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testing at this age. Previous work has shown that high risk women who carry a BRCA1/2
gene mutation are satisfied with undergoing genetic testing and would recommend testing
to others who are at high risk for breast cancer (Klemp, O’Dea, Chamberlain, & Fabian,
2005). The concern for these BRCA1/2 positive emerging adults is what to do after the
genetic test results are disclosed. There are essentially no guidelines for how they should
manage their cancer risks, make life choices, or be counseled regarding reproductive and
surgical options (Hoskins & Werner-Lin, 2012).
Our study gathered information from individuals who received their positive
genetic test result by age 25, in order to provide information to service providers working
with individuals of this age group who have a known positive mutation status.
Information obtained is intended as a useful resource that may make it possible for health
care professionals and genetic counselors to better care for and understand this unique
group of individuals. This information may aid in generating better support and guidance
for individuals of this often overlooked age (Hoskins & Werner-Lin, 2012).
This study built on a small but growing collection of literature regarding emerging
adults with a BRCA1/2 mutation. There has been success with similar studies in the
recent past. The population was not as geographically diverse and the sample size was
smaller. This study offered participants the opportunity to participate in a fully internetbased survey method. This unique study format, when compared to previous works,
enabled us to reach more young mutation carriers (Hoskins, & Werner-Lin, 2012,
Hoskins et al., 2014; Werner-Lin et al., 2012).
We hypothesized that individuals who obtained their positive genetic test result
by age 25 would be satisfied with their decision to undergo testing as well as with the
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choices they have made regarding surveillance and surgery. Further study objectives are
below.
 Comparisons will be made between participants under the age of 25 and participants
age 25 or older at the time of study but had their positive genetic test result by age 25
(Ford et al., 1998; Steinberg, 2005; Werner-Lin et al., 2012)
o We predicted participants under 25 will be less satisfied.
o We predicted participants under 25 would feel their timeline for life is more
affected.
 Life instability was analyzed (i.e., more residency changes/shorter relationships)
(Ford et al., 1998; Hoskins, Roy, Peters, Loud, & Greene, 2008)
o We predicted less satisfaction with undergoing genetic testing.
o We predicted timeline for life and overall life plans would feel more effected.
 Different Types of Metaphors (Comparisons between otherwise unrelated things)
 Have seen and find the role of a genetic counselor important
o More satisfied with their decision to have genetic testing
o Timeline for life and overall life plans feels unaffected by HBOC
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Chapter 2: I Wish I Had Known This! Impact of Age on Life Choices and Testing
Satisfaction for BRCA1/2 Mutation Carriers who
Underwent Genetic Testing By Age 25.1
2.1 Abstract
Objective: To examine if BRCA1/2 mutation carriers who received their positive genetic
test result by age 25 were satisfied with their decision to undergo genetic testing and with
the choices made regarding family planning, surveillance, and surgery. Methods: 72
participants recruited via social media completed a survey hosted by SurveyMonkey.com.
Sixty-three met study criteria and were asked 40 quantitative and qualitative questions
designed to assess family planning, surveillance, and surgery needs of young BRCA
carriers, which included a six question Satisfaction with Decision Scale. Results:
Regardless of age, participants were very satisfied with the decision to undergo genetic
testing. Recommendations were made for the counseling and care of BRCA1/2 mutation
carriers under age 25, which included: (1) Right Reproductive Organs, (2) Risk Reducing
Mastectomy, (3) Risk Figures, (4) Reproductive Options, and (5) Resource for Future.
Conclusions: Participants desired more clear and unbiased care and counseling, where
they felt supported. The complexity of HBOC plus the variable lives BRCA1/2 positive
emerging adults face led us to propose a core set of counseling recommendations for
young BRCA mutation carriers under age 25. Incorporating the five recommendations is
essential to achieving full patient autonomy and unbiased decision facilitation.
_______________________

1

King, S. E., Brooks, K. A., Werner-Lin, A., & Herzog, T. To be submitted to Psycho-Oncology.
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2.2 Introduction
About 10% of individuals with breast and ovarian cancer will have a hereditary cancer
predisposition, which can be passed down in their family. Thirty-five percent of BRCA
carriers will have a mutation in the BRCA1 gene while 37% will have a mutation in the
BRCA2 gene, resulting in a genetic condition called Hereditary Breast and Ovarian
Cancer Syndrome (HBOC). The highest cancer risks are for breast or ovarian cancer.
HBOC syndrome is inherited in an autosomal dominant fashion, meaning that one
mutated copy of the BRCA1 or the BRCA2 gene will cause a predisposition for cancer.
Mutation carriers have a 50% chance to pass on their BRCA mutation to their offspring.
The prevalence of these BRCA1 and BRCA2 mutations in the general population is
between 1/400 and 1/800. It is higher in specific ethnic groups (Petrucelli et al., 2011).
The incidence of de novo mutations in either gene is rare and still unknown (Antoniou et
al., 2003; Clark & Domchek, 2011; Ford et al., 1998).
On average, 60-70% of women with a BRCA1 gene mutation will develop breast
cancer by the age of 70, while an average of 40% will develop ovarian cancer, which
includes fallopian tube and primary peritoneal carcinomas. For women with a BRCA2
gene mutation, an average of 45-55% of women will develop breast cancer by age 70
while 20% will develop ovarian cancer. A lesser yet increased risk has been found for
other cancers, such as pancreatic cancer and melanoma for BRCA2 carriers or
endometrial for BRCA1 carriers (Clark & Domchek, 2011; Segev et al., 2013).
Females who carry a BRCA mutation have a low risk of developing cancer under
age 25. The risk for developing breast cancer before age 30 is about 4.6% (Ford et al.,
1998) while the risk for developing ovarian cancer before age 30 is nearly zero (Stratton
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et al., 1999). Between the ages of 20 to 24, the risk is lower. It is estimated that the
incidence for BRCA1/2 mutation carriers is .02% for breast cancer and .001% for ovarian
cancer (Antoniou et al., 2003). Despite these numbers, BRCA1/2 mutation carriers
between the ages of 20 and 29 have a relative risk of breast cancer 5 to 20 times higher
than that of women of the same age in the general population (Clark & Domchek, 2011).
The individuals targeted by this study who underwent genetic testing by age 25
are among the youngest genetic testing consumers for BRCA1 and BRCA2 single gene
testing. While young, BRCA positive individuals have a low risk for cancer during this
time in life, they may still feel as though they are at high risk for receiving a cancer
diagnosis and may be unsure how to proceed with risk management. Few guidelines
outline empirically-based risk management strategies (Trepanier et al., 2004), much less
how to support life choices, and be optimally counseled regarding medical management
(Hoskins & Werner-Lin, 2012; Hoskins et al., 2014).
The looming lifetime risk for cancer may drive many young individuals to
undergo genetic testing earlier then some guidelines suggest (Ormondroyd et al., 2012).
However, individuals who are 18 to 24 years of age do not yet have a fully developed
frontal lobe of their brain, leading them to have judgment and morality that is not fully
developed (Steinberg, 2005). They are also in a transitional period in life, between ages
18 and 25, known as emerging adulthood. This unique demographic period is when
individuals explore their own identity through the postponement of an adult lifestyle.
Young BRCA mutation-positive individuals are potentially making major choices and
decisions that will impact their lives for years to come. Decisions can include career,
significant other, family planning, and geographic location choices. By the late 20s, most
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individuals have made decisions with lasting consequences. When adults retrospectively
consider key life events, they mainly cite this period as a critical time when life-shaping
decisions were made (Arnett, 2012).
Researchers have examined how having a BRCA1/2 gene mutation impacts this
tumultuous time in life (e.g. Hoskins, Werner-Lin, etc.) and shapes future life for young,
BRCA positive emerging adults (Arnett, 2000). Individuals who are emerging adults and
also from families with an identified BRCA1 or BRCA2 gene mutation may base
decisions regarding normal life transitions upon a timeline of when they expect illness to
occur. Anxiety, worry, and grief regarding disease were found to have an underlying role
in shaping cancer risk perception at this young age (Werner-Lin, 2007).
Current professional medical guidelines available to young, BRCA positive
individuals suggest genetic testing be made available when they reach the age of eighteen
(Trepanier et al., 2004). Previous research has shown that high-risk women who carry a
BRCA1/2 gene mutation are satisfied with undergoing genetic testing and would
recommend testing to others at high risk for breast cancer (Klemp et al., 2005).
However, the concern for these BRCA1/2 positive emerging adults is what to do after the
genetic test results are disclosed. Young, BRCA positive individuals may experience
greater harm and fewer benefits when learning about their BRCA1/2 mutation carrier
status. Compared to individuals older than 25, fewer concrete recommendations exist for
known carriers under age 25. The decision-making processes young mutation carriers
undertake are distinct from older BRCA carriers since there is little published data to
guide what do with this powerful, personal genetic information.
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Support and guidance to assure young, BRCA positive individuals are making
autonomous, informed choices and fully understand the benefits and risks of knowing
one’s mutation status is key (Werner-Lin et al., 2012). Specifically, these young BRCA
mutation carriers desire clearer screening guidelines and continuing support regarding
their medical care over time, as their life and needs evolve (Hoskins et al., 2014).
Patenaude et al. found that one third of the daughters of known BRCA1/2 carriers
reported high cancer-related distress, especially in regards to childbearing. The level of
knowledge about HBOC was suboptimal with many misconceptions about their risk for
carrying a BRCA mutation (2013).
Young, BRCA positive individuals may feel life is now like a waiting game, or
that they are a ticking cancer bomb, even though the actual risk for developing cancer is
low (Kwong & Chu, 2012). Young, BRCA positive individuals react to genetic testing
and cope with information revealed as if cancer will be experienced in the near future
(Hoskins & Warner-Lin, 2012). These fears may push some young carriers to undergo
surgical treatment well before the recommended timeframe.
Young, BRCA positive individuals may seek risk management advice from their
primary health care providers, surgeons, or gynecologists. Health care providers are
unlikely to be trained to handle the sensitive nature of these topics for this age group.
Unlike many other mutation positive individuals, emerging adults’ surgical decisions
cannot be made quickly. This group needs support to assure that they have considered
the complexities related to their decision and its potential ramifications over the life
course (Werner-Lin et al., 2012).
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BRCA1/2 positive emerging adults are unique in the sense that the traditional
options given to individuals, such a surgical choices and reproductive planning, may not
seem to apply at the time of genetic test result disclosure. Reproductive issues and
surgical options may be highly appropriate subjects for young carriers to learn of in a
genetic counseling session, since they may not have not begun or completed their
families (Kwong, & Chu, 2012; Ormondroyd et al., 2012). The ability to carefully think
ahead and plan for the future is a unique opportunity this group has, when compared to
older BRCA1/2 carriers. The sensitive and complex nature of the topics related to BRCA
as well as the likelihood that they will have an impact on each individual’s life requires
careful discussion with trained health care providers to navigate through possible issues
(Ormondroyd et al., 2012). Fear of developing cancer may lead some to undergo
surgeries or surveillance while for others the waiting game may elicit ongoing anxiety.
Guidelines suggest that high-risk individuals could start screening at age 25 or at
10 years prior to the earliest age of diagnosis in their family (Berliner et al., 2013;
Trepanier et al., 2004). Recommendations typically bypass this group. It is
recommended that annual mammograms and breast MRIs should begin at age 25.
Clinical breast exams (CBE) should be done annually or bi-annually starting at age 25
(Berliner et al., 2013). At the age of 30, women can elect to have CA-125 screening and
transvaginal ultrasounds to screen for ovarian cancer, even though the utility has yet to be
proven for ovarian cancer screening. Chemoprevention may be considered. Oral
contraceptives have been known to decrease the risk of ovarian cancer up to 45-60% if
used over a period of five years in high-risk women who have a history of ovarian cancer
(Berliner et al., 2013). Medications such as tamoxifen or other chemopreventive drugs
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reduce the risk of developing breast cancer as well, reducing the risk for invasive breast
cancer by about 44% for women 49 and younger (Fisher et al. 1998).
Two main risk-reducing surgical options are available for women with a BRCA1/2
gene mutation. Risk reducing bilateral mastectomy would reduce the risk of breast
cancer by at least 90%. There is no standard age for which this is recommended. A riskreducing bilateral salpingo-oophorectomy (BSO) would reduce the risk for ovarian
cancer by 80-96% and reduces the risk of breast cancer by up to 50% in women who
have not yet gone through menopause. Surgery recommendations are for BRCA1/2
positive women ages 35 to 40 (Berliner et al., 2013).
This study built on a growing collection of literature on emerging adults with
BRCA1/2 mutations (Hoskins & Werner-Lin, 2012; Hoskins et al., 2014; Werner-Lin et
al., 2012). We aimed to reach a greater number of geographically diverse participants by
offering the opportunity to complete an internet-based survey. We gathered information
from individuals who received their positive genetic test result by age 25 with the
intension of making this information available as a resource for health care professionals.
This information will enable providers to better understand the unique support and
guidance needs of these very young BRCA1/2 carriers (Hoskins et al., 2014).
We hypothesized individuals who obtained their positive genetic test result by age
25 would be satisfied with their decision to undergo testing as well as with the choices
they have made regarding surveillance and surgery. Further study objectives are below.
 Comparisons were made between participants under the age of 25 and participants age
25 or older at the time of study but had their positive genetic test result by age 25:
o We predicted participants under 25 will be less satisfied.
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o We predicted participants under 25 would feel their timeline for life is more
affected.
 Life instability was analyzed (i.e. more residency changes/shorter relationships):
o We predicted less satisfaction with undergoing genetic testing.
o We predicted timeline for life and overall life plans would feel more affected.
 We predicated finding numerous metaphors (comparing two unlike things).
 We predicted participants would recommend seeing a genetic counselor.
o We predicted more satisfaction with the decision undergo genetic testing.
o We predicted timeline for life and overall life plans would feel less affected.
2.3 Materials and Methods
2.3.1 Sample Selection Criteria. Participants recruited were BRCA1 and BRCA2
mutation positive individuals who underwent genetic testing before age 25. Criteria for
selecting participants included (1) BRCA1 or BRCA2 mutation carriers, (2) over age 18 at
the time of the study, (3) received their genetic test result before age 26, and (4) English
speaking. Participants could be of any age at the time of the study. Participants not
meeting criteria were excluded. Unlike previous works (Hoskins & Werner-Lin, 2012;
Werner-Lin, et at., 2012), we did not exclude participants who had received a cancer
diagnosis. While the study did invite male participation, the final participant pool
included solely women.
2.3.2. Recruitment. Participants were recruited using convenience and purposive
sampling. Participant recruitment was open from September 30, 2013 to February 6,
2014. Recruitment proceeded via different forms of social media (Appendix A).
Standardized recruitment announcement templates were designed to maintain the
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consistency of the invitations for the participants (Appendix B). Each message was
tailored to fit the type of social media or online forum. Templates contained an
embedded link to the survey and contact information for the investigators.
Recruitment proceeded via invitation posted on three FORCE message boards.
Messages were posted on the Main Forum, the Young Previvors Forum, and the Research
Opportunities Forum. Further recruitment proceeded through Bright Pink via two tweets
from their Twitter account. Facebook groups and blogs related to BRCA aided
participant recruitment by posting messages containing the survey link on their pages.
Each Facebook group was contacted by direct message prior to the posting being made.
2.3.3. Survey Design. An online survey was constructed by the researcher. A survey
from a related, previous work was utilized to guide question creation (Werner-Lin et al.,
2012). The final survey was reviewed and approved by the thesis advisory team. The
study was hosted on SurveyMonkey.com. It consisted of forty questions designed to
assess both participants’ satisfaction with their decision to undergo genetic testing and
participants’ feelings about life choices made (Appendix C). The 40-question survey
included:


Yes/no with corresponding open-ended prompt (15 questions)



Demographics and participant characteristics (11 questions)



Open-ended (5 questions)



Satisfaction with Decision Scale (SWDS) (6 questions)



Likert-scale style questions (2 questions)



Yes/no to follow-up call with link to a support resource (1 question)
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The 15 yes/no questions each had a quantitative and a qualitative component,
which was designed to assess how a positive genetic test result affected decision-making
and life choices made. Among these yes/no questions were three questions regarding life
planning. The life planning choice questions included asking participants if they had a
medical management plan in place, if they had received genetic counseling, if they had
been informed about family planning or reproductive options. The Likert scale-type
questions were designed to assess the degree of worry over life events and the helpfulness
of specific types of healthcare providers. The life events included finding a job, finding a
place to live, completing school or duties at work, finding a partner or getting married,
having children or family planning, and reducing your risk for cancer via surgery,
treatment, etc. Open-ended questions were designed to assess participant perception of
cancer risk or knowledge gained through BRCA-related experiences. Participants were
asked to share advice for future BRCA1/2 positive people under age 25.
The demographic and participant characteristic questions were used to obtain data
on current age, age at time of genetic testing, sex, race/ethnicity, personal income, and
highest educational level. Individuals were asked if they have a BRCA1 or BRCA2 gene
mutation. Current relationship length and the number of residence changes in the past
eight years were asked to assess life stability, since these two factors change frequently
for many emerging adults (Arnett, 2000). Participants were also asked if they had been
pregnant and the number of sons or daughters that they have. In the final question of the
survey, participants were asked if they would be willing to receive a follow-up phone
interview if needed. Participants who responded yes were asked to leave their contact
information. Participants were provided the link to the “find a genetic counselor” feature
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on the National Society of Genetic Counselors (NSGC) website at the in case they felt
distressed or in need of additional support. No follow-up phone calls were made.
To determine participant satisfaction with undergoing genetic testing, a previously
developed survey tool was used. It was designed to gauge satisfaction with health care
decisions (Holmes-Rovner et al., 1996). The Satisfaction With Decision Scale (SWDS)
is positively correlated with decision-making confidence and has a proven reliability of
86%. It had a Cronbach’s Alpha score of 0.86. The aim was to see if participants were
satisfied with their decision to undergo BRCA1/2 genetic testing at a young age.
The SWDS questions were reviewed and analyzed via a Cronbach’s Alpha test,
like Holmes-Rovner et al. (1996). It was expected to be reliable since the SWDS had
been proven reliable previously in a study of BRCA1/2 mutation carriers who underwent
genetic testing after using a computer-based decision aid (Green et al., 2004). The
SWDS also is a concise way to evaluate participant satisfaction with undergoing genetic
testing. We desired to minimize the potential for loss of participants due to the length of
the survey overall (Holmes-Rovner et al., 1996; Kasparian & Wakefield, 2007). This
research study was approved by the Institutional Review Board, Office of Research
Compliance, of the University of South Carolina, Columbia, SC.
2.3.4. Data Collection. Participants were targeted via a variety of social media venues.
Participants who clicked on the embedded survey link, which was found in each of the
invitation to participate templates, were brought to the first page of the study. The first
page consisted of a consent document that explained the goals of the study, potential
benefits and risk to participants, and the contact information for the primary researcher as
well as the director of thesis. Following the consent document, the survey consisted of
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eight pages of questions. Once data collection was complete, all data was downloaded as
excel files and stored on a password-protected computer.
2.3.5. Data Analysis. The primary researcher met with a statistician to develop an
overall plan for quantitative data analysis. SPSS predictive analysis software, version
22.0, was used to analyze of the quantitative data. Chi-square test with Fisher’s exact test
was used to determine correlations and infer independence among categorical data. The
categorical data included participants responses to questions such as educational level
reached. Spearman’s Rho was employed to determine correlations and infer
independence for the ordinal data. The ordinal data included participant responses to
questions such as the length of time they have been with their current partner and their
number of residency changes. Percentages were used to review and depict what percent
of young mutation carriers were concerned about specific life events, such as finding a
job or reducing their cancer risk. Cronbach’s alpha was preformed to confirm the
validity of the SWDS tool.
Data from the open-ended questions was analyzed using Content Analysis.
Participant responses were printed onto paper, cut into strips, and color-coded based on
the content of each participant’s response by the researcher. Recurring themes and trends
in the overall data were obtained. Frequency counts based on the number of times a
particular theme was mentioned in a participant response were obtained. Tables and
figures were developed to visually display key findings and participant demographics.
2.3.6. Benefits and Risks of Study. This study provided no direct benefits or risks to
participants. Young, BRCA positive individuals may have benefited by having the
opportunity to express the knowledge and experience gained through past experiences
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(Birch & Miller, 2010). Enabling young, BRCA positive women to share and describe
their experiences has potential therapeutic benefits, especially if they felt as though they
were helping others (Ziebland et al., 2013). The risks to participants were minimal.
When thinking about their own past experiences, participants may have felt sad or upset
by their circumstances, decisions, or changes in life.
2.4 Results
2.4.1. Participants. Responses were gathered from 72 participants, but 63 met study
criteria (N = 63) (Figure 2.1). At the time of survey, about 40% of participants were
under age 25 while about 60% were 25 or older (Figure 2.2).

All Study
Participants
(n = 72)

Particpants Meeting Criteria

~ 40%

Participants who had their
BRCA1 and BRCA2 test

Under Age 25

result by age 25
(N = 63)

Age 25 or Over

~ 60%

Figure 2.1. Criteria for study participation.

Figure 2.2. Participant ages at the time of study.
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Participant ages are shown in Table 2.1. Participants’ average age at the time of
results disclosure was 22, while the most commonly reported age was 24. The average
age at the time of survey was 26, but most participants were age 24. Most participants
were White/Caucasian (87%), held a Bachelor’s degree (32%), had an average personal
income between $30,001 and $50,000 (37%), and had no children (67%). Most often,
participants changed their place of residency three times in the past eight years and had
been with their spouse or partner an average of three years.
We met our goal of exceeding 60 participants; however, our sample size
lacked diversity in terms of sex, race or ethnicity, highest educational level, and income.
All participants were women, a large majority were White or Caucasian (87%), over 60%
had achieved a Bachelor’s degree or beyond and had personal incomes of $30,0001 to
$50,000 or greater. Geographically, our study succeeded in reaching out to participants
beyond the United States. Facebook groups utilized in obtaining research subjects
included at least three groups based out of Canada or the United Kingdom. Among
participant responses, at least six participant responses acknowledged that they were
located or had received care and services at countries outside of the United States.
2.4.2. Satisfaction. The reliability of the six question Satisfaction with Decision Scale
(SWDS) as a single composite score for overall satisfaction with the decision to have
genetic testing was determined using a Cronbach’s alpha test (α = 0.835). Alpha scores
were above 0.70 indicating that the SWDS showed good internal reliability and was
effective at assessing participants’ satisfaction with the decision to undergo genetic
testing. Table 2.2 lists the six questions that make up the SWDS.
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Table 2.1. Participant characteristics and demographics.

Age genetic test result received (years)
Age at time of survey (years)
Children (n = 35)
Total
Number of daughters
Number of sons
Residency changes (last 8 years) (n = 47)
Years with current spouse/partner (n = 42)
Sex
Female
Age at time of survey, by age group
Under 25
25 and Over
Gene with mutation identified (n = 63)
BRCA 1
BRCA2
Unsure
Race/ethnicity (n = 47)
American Indian or Alaskan Native
Hispanic American
White/Caucasian
Other
Education (n = 47)
Finished high school or GED
Some college education
Associate's degree
Bachelor's degree
College beyond a bachelor's degree
Personal Income (n = 43)
Less than $12,000
$12,0001 to $30,000
$30,001 to $50,000
$50,001 to $100,000
More than $100,000
Pregnancy (n = 46)
No
Yes
N/A

Average

Range

Mode

22
26

16-25
19-40

24
24

0.7
0.3
0.3
3
5
N

0-4
0-2
0-2
0-8
0-15
%

0
0
0
3
3

100%

28

19
28

40%
60%

37
25
1

59%
40%
1%

1
1
41
4

2%
2%
87%
9%

3
9
7
15
13

6%
19%
15%
32%
28%

8
4
16
14
1

19%
9%
37%
33%
2%

31
14
1

67%
30%
3%

Table 2.2. SWDS questions and response options.
The Satisfaction with Decision Scale: Decision to have genetic testing
1. I am satisfied that I was adequately informed about the issues important to my decision.
2. The decision I made was the best decision possible for me personally.
3. I am satisfied that my decision was consistent with my personal values.
4. I successfully carried out the decision I made.
5. I am satisfied that this was my decision to make.
6. I am satisfied with my decision.
Response options:
1- strongly disagree, 2- disagree, 3- neither agree nor disagree, 4- agree, 5- strongly agree

Average scores for the SWDS were determined using an ANOVA test, and then
compared to participant ages at the time of testing. An ANOVA test was used for the two
age categories, to see if there was a difference in testing satisfaction. Results are shown in
Table 2.3. Although participants under the age of 25 had slightly higher satisfaction with
their decision to undergo genetic testing than the 25 or older age group, this difference
was not statistically significant.
Table 2.3. SWDS and age at time of study.
Overall
Age group
Under 25
25 and over

N
63

Average Score
4.7

Standard Deviation
0.66

19
28

4.8
4.6

0.28
0.82

The SWDS was compared to the two participant age groups at the time of study,
education level, and personal income to see if relationships between participant
demographics and satisfaction were associated with the decision to undergo genetic
testing. The SWDS was also compared to participants’ life planning. Life planning
choices included yes or no responses about their BRCA status affecting their timeline for
life or overall life plan. It also included if they had a medical management plan in place,
if they had met with a genetic counselor, or if they had been informed about family
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planning or reproductive options. These comparisons were performed using ANOVA
test. The results are shown in Table 2.4.
To assess participant satisfaction with the decision to undergo genetic testing,
ANOVA was used to compare whether or not a participant thought their positive
BRCA1/2 mutation status had an effect their overall life plan. This was statistically
significant (p = 0.04). Therefore, participants who report life plans were impacted by
their BRCA1/2 positive result were more likely to report an effect on their satisfaction
with undergoing genetic testing. The most satisfied participants still reported that
knowing that they were BRCA1/2 positive impacted their overall life plans. Therefore, it
seemed that regardless of the outcome BRCA had on participants’ lives, they still were
still pleased with their decisions to have genetic testing.
Table 2.4. SWDS vs. participant demographics and life planning choices.
df
between-groups

within-groups

F

p

Age at time of study, by age group

1

44

1.04

0.32

Education

4

38

1.24

0.31

Personal income

4

44

0.16

0.70

Timeline for life

1

51

1.5

0.23

Overall life plan

1

51

4.55

0.04*

Medical management plan

1

51

0.61

0.69

Genetic counseling

1

51

0.14

0.71

Family planning or reproductive options

1

50

0.08

0.78

2.4.3. Quantitative Data Regarding BRCA-Related Experiences and Choices.
Participants answered 15 yes or no questions about experiences and choices they have
made related to BRCA (see Table 2.5). Nearly half of participants reported that their
overall life plans or goals they desired to achieve were affected by testing positive for the
BRCA1/2 gene mutation (57%). Nearly three-quarters of participants responded that
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testing positive for a BRCA1/2 gene mutation caused them to feel as though the speed of
their timeline for life events was altered (71%). A majority of participants had not
received a cancer diagnosis (95%), were undergoing breast screening (77%) with normal
outcomes (65%), had undergone some form of breast surgery (58%), and had not
undergone a surgery related to the ovaries or female reproductive organs (85%). Only
2% of participants had utilized chemopreventive drugs. A majority had a medical
management plan in place (88%) and all had considered risk-reducing surgeries (100%).
Most received genetic counseling (84%). A majority of participants had not been
introduced to reproductive or family planning options, such as PGD (preimplantation
genetic diagnosis) with IVF (in-vitro fertilization), adoption, or surrogacy (52%).
Education level was compared to the three life planning choice questions and age
at the time of the study (See Table 2.6). A significant association was found between
participant education and if they had received genetic counseling, χ2(4, N = 51) = 11.16,
p = 0.03. Participants were more likely to have had genetic counseling if they had
reached a higher level in their education.
Regardless of age, most participants reported a mild level of worry about reducing
their risk for cancer. More participants under the age of 25 selected the high level of
worry option (16%) when compared to those age 25 or older (6%) regarding reducing
their risk for cancer. The under 25 group also tended to have more worry regarding
completing school or duties at work, with 26% selecting the high concern option. Only
10% of the women in the 25 and older group expressed high worry over school or work
duty completion. A majority of women under age 25 expressed a low level of worry with
finding a partner or getting married (32%) and having children or family planning (37%),
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while most of those age 25 or older said they were not worried (71% and 45%,
respectively) and think about these rarely. A majority of women who participated in this
study expressed none to low or mild worry levels regarding these life event categories.
Table 2.5. Participants’ experiences and choices related to BRCA.
Question

Yes

No

Q3: Have you ever been diagnosed with cancer? (n=59)

5%

95%

Q4: Have you ever had a mammogram, MRI, breast ultrasound, or
breast imaging study? (n=60)

77%

23%

Q5: Have you ever had an ABNORMAL mammogram, MRI, breast
ultrasound, or breast imaging study? (n=60)

35%

65%

Q6: Have you ever had a normal or abnormal tissue biopsy? (n=59)

20%

80%

Q7: Have you ever had breast surgery? (lumpectomy, mastectomy,
etc.) (n=59)

58%

31%

11%

Planned but not
taken place

Q8: Have you ever had a surgery related to the ovaries or other
female reproductive organs? (Hysterectomy, tubal ligation,
conization, bilateral salpingo oophorectomy, etc.) (n=59)

14%

85%

1%

N/A

Q10: Have you ever considered having a surgery to reduce your risk
of cancer? (n=59)

95%

5%

Q11: Have you ever used any chemopreventive drugs? (Ex:
Tamoxifen, Evista, etc.) (n=57)

2%

96%

2%

N/A

Q13: Do you think testing positive for a gene mutation affected the
timeline for your life? For example, do you feel like you need to
speed up or slow down some of your plans for the future? (n=51)
Q14: Do you think testing positive for a gene mutation affected your
overall life plan? (Ex: desire to have children, marriage, etc?) (n=51)

71%

29%

34%

57%

Q15: Do you currently have a plan in place for your future health
care, related to your positive BRCA genetic testing result? (Ex: have
a medical management plan including starting mammograms at an
early age and....) (n=51)

88%

12%

Q18: Have you ever received genetic counseling? (n=49)

84%

16%

Q19: Have you ever considered a risk-reducing surgery? (n=49)

100%

0%

Q20: Have you been introduced to different types of family planning
or reproductive options based on the mutation in your BRCA gene?
Examples may include: PGD (preimplantation genetic diagnosis)
with IVF, adoption, surrogacy, etc. (n=52)

48%

52%
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Other

Table 2.6. Participant level of concern or worry regarding life events (%).
Percentage of Participants at Each Level of Concern or Worry (%)

Finding a job

Finding a place to live

Completing school or
duties at work
Finding a partner or
getting married
Having children or
family planning
Reducing your risk
for cancer (surgeries,
treatment, etc.)

Think about
rarely:
None

Think about
once/twice a
month:
Low

Think about a
few days a
week:
Mild

Think about
daily:
Moderate

Think
about
Constantly:
High

58%

5%

11%

16%

11%

65%

6%

19%

0%

10%

58%

26%

5%

11%

0%

77%

10%

3%

10%

0%

32%

5%

16%

21%

26%

42%

19%

19%

10%

10%

26%

32%

16%

16%

11%

71%

13%

6%

3%

6%

11%

37%

32%

11%

11%

45%

32%

16%

6%

0%

5%

26%

42%

11%

16%

23%

19%

29%

23%

6%

Key: Participant age at time of study, by group: Under 25 (n=19) 25 and over (n=31)

Participants were asked to rate how helpful or unhelpful specific types of
healthcare providers were at providing support and guidance. They were asked to say if
they found them very helpful, somewhat helpful, neither helpful or unhelpful, somewhat
unhelpful, or very unhelpful (shown in figure 2.3).
The number of years participants were with their partners and the number of
residency changes participants had in the past eight years were asked to gauge life
stability. These questions were compared to whether or not participants felt that their
positive BRCA1/2 mutation status affected their timeline for life or their overall life plans.
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These questions were compared using an ANOVA test. There was no significant effect
between years with partner and timeline for life, F(1, 32) = 0.89, p = 0.35. There was no
significant difference between the number of years with partner and overall life plan, F(1,
32) = 0.46, p = 0.50. There was no significant difference between number of residency
changes an timeline for life, F(1, 34) = 0.16, p = 0.70. No significant difference between
number of residency changes and overall life plan was found, F(1, 34) = 0.01, p = 0.92.

Figure 2.3. Healthcare services rated by their provision of support and guidance.
2.4.4. Themes.
Life experiences and outlook. Participants reported details about experiences
they have had with family members or healthcare providers. Participants wrote responses
regarding their outlook on life after testing positive for a BRCA1/2 gene mutation (see
Table 2.8), which were analyzed for common themes. Most often, participants had an
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accurate perception of their cancer risk (n = 22) while many others either overestimated
their risk (n = 16) or quoted the correct risk figures, yet said they thought their risk was
higher based on their family history (n = 14). Most also noted seeing family members
fight against caner (n = 38). A main theme was that knowledge of their BRCA1/2 had a
positive impact and they were hopeful for the future. Participants wrote that it as a
chance to seize opportunity (n = 14) or that it would not alter plans (n = 9).
Positive Outlook.
- I still had children, got married, lived it up in my early 20s, went to
college. BRCA positive results did not slow my life down. They gave me
the tools I needed to ensure my life would go on.
BRCA was a Positive that Led to a Career Change.
- Testing positive and confronting my risk via preventative mastectomy
changed my perspective on life drastically. While I always valued health,
being a good person, and contributing to the world in a meaningful way,
prior to my surgery I wasn’t actively pursuing these priorities. My career
plans have changed – rather than staying in the field of marketing I am
pursuing graduate school for epidemiology. I pursue goals because I
believe they are meaningful and will fulfill me, rather than for the
appearance of success. As much of a burden as testing positive is, it is
also a blessing in disguise if you let it.
- Made sense that I would be [positive], I can help so many with what I
have access to and what I know as a nurse, and personal experience now
with surgery, and passion fueled by loss of life in family members.
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Table 2.8. Life experiences and outlook.
Life experiences and outlook (n = 168)
Family history shaping perception of risk
Accurate perception of cancer risk
Overestimating cancer risk
Quote accurate numbers, but believe it is higher because of family history
Underestimating cancer risk
Overestimate risk before to prophylactic surgery, now underestimate risk
Metaphors as a way to think about cancer risk
Quote accurate numbers, but believe it is higher because had cancer
Witnessed family members fight against cancer
Chance to seize opportunities
Positive impact on life plan / led to specific career path
Eat healthier and spend more time with family
Always felt there was no time to waste because of family history
Travel more
Conflict about what is best for young carriers
Tried to talk out of having prophylactic surgery
Pushed to have a family before they felt ready
Tried to talk participant into having reconstruction
Did not want to work around college class schedule
Physician disagreement over hormone replacement therapy use
Difficulty providing appropriate care for young carriers
Doctor uninformed about BRCA and not knowing how to provide care
Genetic counselors with recommendations not fitting for someone so young
BRCA will not alter plans
Altered self-image
Due to mastectomy
Due to screening or biopsy
BRCA as a death sentence
Is not a death sentence
Felt like a death sentence
Denial about cancer risk
Recent or impending loss of a family member as a reason for denial
Did not expect to be BRCA positive
Feelings of hopelessness
Concerns involving insurance
Planned for a career with good insurance because of BRCA
Concerns over future insurance coverage, even though protected by law now
Knowing your mutation status as a blessing
Angelina Jolie’s decision as eye opening

n
60
22
16
14
3
2
2
1
38
14
4
4
4
2
12
3
2
1
1
1
9
4
3
9
6
4
2
5
4
1
5
4
1
3
3
2
1
2
2

Overestimation of cancer risk.
One participant wrote: I believe my risk would be approaching 100% every woman on the BRCA1+ side of the family has battled cancer more
than once, my aunt has had 8 diagnoses of cancer in the last 30 years. I
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am the first to have engaged in risky behaviors such as smoking and heavy
alcohol consumption. Statically I know that my breast/ovarian risk is
quite low now, however with a 53% chance of surviving to the age of 70, I
have decided to approach my carrier status as absolute, otherwise I fear
gambling with statistics might cost me my livelihood or my life.
Another wrote, “95% because both my grandmothers had breast cancer and my
mother had both breast and ovarian cancer and now that I know I have a BRCA1 gene
mutation I know my risk is vary high.” A third explained, “I had a 98% chance by age
30, it wasn’t an option to not be preventative [and undergo mastectomy].” Another
participant used a metaphor to explain her risk: “Before surgery, it was 55-85% [for
breast cancer] …for ovarian 10-60%, ‘average risk of 31%’. The way I see it, even if my
risk for breast cancer was ‘only’ 45 or 55%, I made the right decision for me in having
prophylactic surgery. If you knew that ‘only’ 1 out of 2 vehicles sold by a particular
manufacturer exploded spontaneously, would you still buy the car?”
Affected Self-Image.
- [I had] double-mastectomy with skin and nipple-sparing reconstruction.
The months leading up to the surgery were the worst part emotionally.
The anticipation and emotional preparation for losing a part of your body,
particularly a part so close tied to your womanhood, is extremely difficult.
I struggled with the fact that I wouldn’t be able to feel my breasts
anymore, that I wouldn’t be able to breast-feed, and that I had no
guarantee I would ever look “normal” again. Recovery was difficult, but
manageable with pain medication. The hardest part for me was giving up
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my mobility (not being able to use my arms, drive, exercise – even if I
wasn’t in pain) until my drains were removed… The expansion process
brought on insecurities – did my boyfriend still find me attractive? Did
people get weirded out when I hugged them and my boobs felt hard as
rocks? I pushed through… The overall result has been fantastic.
Cosmetically? My boobs rock. Better than my natural ones ever were. I
had a great doctor!
- I had a normal MRI guided core biopsy. …This experience was
considerably more trying then expected… I was surprised how negatively
my self-image was affected by the procedure, the busing, the pain in my
breast. It also brought forward thoughts and concerns of how I will be
able to cope if I choose to go forward with surgeries in the future. I found
these concerns in addition to the stress of the procedure to be more
stressful than any worry about potential results.
Denial.
- Anyone who asked, I told them I was 95% sure I did not carry the gene,
so I had no concern about being told [my result] over the phone. I got the
call at home while my daughter was napping, and it was just me. I was
devastated. I could not get off the phone fast enough because I just
wanted to sit and cry by myself. After I calmed down, I called my
husband at work and told him, and then cried all over again. …It was a
major shock to me.
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Hopelessness. Two participants wrote about hopelessness in relation to finding
out their test result. One replied, “Mixed [thoughts on prophylactic surgeries]. I suspect
I will do them and then die of pancreatic cancer at 60. So it feels a bit useless. Then
again better to die at 60 than at 35 I guess.” Anther wrote, “There was a certain amount
of hopelessness that came along with my test results… it paralyzed me for a long time.”
Impact of Angelina Jolie’s Decision.
- I eventually came to the tentative decision that a prophylactic
mastectomy was something I’d be interested in doing as soon as I moved
back to the states. And then Angelina Jolie wrote that article about her
own decisions and suddenly all I could focus on were the negative
comments.

People calling her surgery ‘self mutilation’ and an

overreaction. I started to back-track a little. Was the decision I had come
to (independent of her article) short-sided? Was I only doing it out of
panic? I threw myself back into researching the same things I had before,
but this time I had the added bonus of doing it AFTER everyone had read
Jolie’s article and suddenly there was this wealth of information and
firsthand stories that I hadn’t seen before. It was much easier for me to
find stories and blogs of girls MY AGE who has gone through the same
surgery and explicitly stated how much they didn’t regret the decision.
- I received my results in a meeting with my genetic counselor. Honestly,
at the time I had no idea what it meant at that time and couldn’t
understand why the counselor seemed so serious. I’d just lost my dad, so I
guess it didn’t really sink in. …I really had no idea of the gravity of the
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situation until mid-2013 when Angelina Jolie announced her PBM – I
thought wow, that’s serious. So even though it was in the back of my
mind for seven years or so, and I suffered a lot of fear from the uncertainty
and my own ignorance, I only began to take it seriously after being
catapulted into the BRCA world by a celebrity. Even though I have seen
all the women on my dad’s side suffer from HBOC syndrome and all but 2
of the have died because of it.
Insurance.
- I decided to this surgery NOW because I have found myself in a very
specific position: I had just moved back to the states and was unemployed;
I was under the age of 26 and could join my parents’ health insurance
plan; and would be living in a house with people who had already hone
through the aftercare process with my mom & would know what to
expect. Delaying my job search for a year (my biggest hang up) seemed a
lot more logical to me under those circumstances.
- I had different priorities in my early 20s even before testing because of
my family history, e.g. having a job that provided health insurance.
Obamacare would have changed that for me if I was younger because I
could have stayed on my parents’ plan.
Screening. Participants mentioned topics related to screening 128 times (n = 128).
Main themes and the number of times participants reported specific details about
screening are shown in Table 2.9.
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Unfavorable Screening. For one, “It was really uncomfortable because I had
dense breast tissues since I was young and hadn’t had any kids yet.” Another reported,
“The mammogram was awful. The lady kept squishing them even after I said I couldn’t
take it anymore. The ‘pads’ were of no help. The ultrasound was completely okay. It felt
like a massage made specifically for my boobies.”
Others wrote, “I have not enjoyed any of them [surveillance]. I find it brings me
down and reminds me of being ill when I’m not” and “Anxiety could be the best way to
describe my experience to all the tests I went through. I was constantly worried they
were going to find something and I would have to go through surgery, chemo, and
radiation like my mom.”
- It was a very stressful experience to even consider that I may have
cancer. The needle biopsy itself was invasive and painful. In fact, this
was probably the most traumatic experience I have had in dealing with my
BRCA2 mutation (and I underwent a double mastectomy at age 22!).
Surgical Decisions. Responses were evaluated for themes using Content
Analysis. The number of times participants made comments related to surgical decisions
were counted and summarized in Table 2.7. Most participants mentioned surgical
choices they either have made or will make in the future (n = 100). The most commonly
mentioned surgery was prophylactic bilateral mastectomy (n = 40). Other trends in the
data included waiting until after having a family (n = 29), having reconstruction (n = 18),
having a oophrectomy in the future (n = 18), and being shaped by watching other family
members experience cancer (n = 20). Fourteen people had misconceptions about surgical
choices, with most noting either that they had or hoped to have a hysterectomy (n = 11).

41

Table 2.7. Surgical choices and decisions made.
Surgical Decisions (n = 234)
Surgery choices made or will make
Mentioned that they had prophylactic bilateral mastectomy (ages noted: 21, 22, 25, 28, 37)
Nipple sparing
Bilateral mastectomy (following unilateral cancer diagnosis)
Reconstruction
Expanders then implants
Expanders, implants, and nipple reconstruction
Direct to implants (age 28)
Tissue expanders then saline implants (age 28)
Silicone implants (age 29)
Will have prophylactic bilateral Salpingo oopherectomy and/or hysterectomy
(Ages: after 30, max 35, around 35, at 38, around 38, at 38, by 40, at 40, or after 45)
Will have prophylactic bilateral mastectomy (by 30, at 30, around 35-40, or before 40)
Non-nipple or skin sparing
DEIP flap reconstruction (age 27)
Had bilateral Salpingo oopherectomy and/or hysterectomy (ages: 26, 27, 29, and 38)
Davinci hysterectomy
No reconstruction
Surgery after children
Already had / plan to have mastectomy, wait for oopherectomy
Wait for both mastectomy and oopherectomy
Desire to breastfeed children
Surgery is "the best option"
It was worth it
I am young so recovery will be easier and faster
Best option because no longer wanted to live life waiting for cancer
The only option for me personally
Family history shaping surgical choices
Surgery because witnessed family members fight with cancer
Do not want to children to have to watch me fight cancer
Mastectomy and later oopherectomy because family members have chosen this
Surgery "to prevent cancer"
Misconceptions about surgeries warranted because of a BRCA1/2 mutation
Noted hysterectomy or removal of uterus
Only fallopian tube removal
Oopherectomy not an option until after 45
Noted cervical dysplasia and abnormal pap smears as motivation to undergo surgery
Bilateral mastectomy to alleviate worry
Set mind at ease / freedom from stress
Reduce stress caused by surveillance and the potential to find cancer
Unforeseen issues with surgery plans
Surgical course was more painful and complicated than expected
Skin necrosis and low blood flow following prophylactic bilateral mastectomy
Problems with infection due to the skin not healing
Complications with drains
Lumpectomy led to more serious surgery due to positive nodes
Frustration over length of time it took have surgeries completed
Surgery to gain control over cancer
Early menopause concerns
Concern that bilateral mastectomy will affect sex life
Insurance dictating timing of surgery
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n
100
40
2
2
18
2
2
2
1
1
18
12
2
2
9
1
1
29
23
6
3
22
4
3
3
2
20
11
5
4
16
14
11
1
1
1
13
8
5
6
4
3
2
1
1
2
5
4
3
2

Mastectomy Prior to Childbearing.
- I originally planned to have a bilateral mastectomy after having children.
I finally came to a point where I was not willing to take the risk of getting
pregnant and going without effective surveillance for 9 months, while my
body went through hormonal changes.
Family Experiences Impacting Surgical Choices.
- At age 28, I had a [PBM]. My mom was only 29 when she was
diagnosed with breast cancer, and she passed away at age 35 when I was
only 6 years old. I have two of my own young children and I vowed to do
everything I could to avoid this happening to us. It has been a long road,
recovery hasn’t been easy, but I haven’t for a minute regretted it.
- I had prophylactic bilateral mastectomy when I was 22. I watched my
mother get diagnosed and fight breast cancer twice and I was determined
to stop cancer before it got me. I wanted to prevent my children and
family from going through what I went through watching my mom.
Healthcare and Support. Participants mentioned topics related to healthcare or
support 115 times (n = 115). Main themes and the number of times participants reported
specific details about healthcare support are shown in Table 2.10.
Major themes among participant responses included participants feeling either
supported by their health care providers (n = 61) or frustrated by them (n = 16). Most
participants recommended seeing a genetic counselor (n = 14). Other women
recommended finding other people who are also BRCA1 or BRCA2 positive (n = 10).
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Table 2.9. Screening plans and thoughts on the options available.
Screening (n = 128 )
Screening protocol in place
Yearly MRIs
Every six months, CA-125 and transvaginal ultrasound
Breast ultrasound, mammogram, and MRI (alternating)
Every six months mammogram or MRI (alternating)
Breast ultrasound and MRI (alternating)
Yearly Mammograms (starting at ages 21, 35 30, or after testing positive)
Yearly
Birth control as a way to reduce the risk for ovarian cancer
Undergoing screening for melanoma / seeing a dermatologist
Concerns about pancreatic cancer because of family history
Biannual breast MRI (post mastectomy)
Yearly mammograms and MRIs. (start at age 21)
Yearly mammograms and breast ultrasounds
Yearly CA-125
UK has no ovarian cancer screening options
Biannual CA-125
Every three months CA-125 / every six months pelvic ultrasound
Surveillance causing anxiety and stress
Toll on mental state
Stress over length of time an MRI takes
MRI is nerve-racking
Anxiety waiting for results after screening
Surveillance as frightening because of family experiences with cancer
Misconceptions about screening warranted because of a BRCA1/2 mutation
Pap smears as screening
Concerns for cervical cancer screening because in family history
Need for colonoscopy
Mammogram as painful or uncomfortable
Dense breasts
Large breasts
Core needle biopsies or fine needle aspirations were painful
Rechecks are more of a hassle or inconvenience
Frustration obtaining insurance coverage for screening because of age
Surveillance causing no pain or stress

n
92
12
11
11
9
8
6
5
5
4
4
4
3
3
3
2
1
1
16
5
4
2
2
1
7
4
2
1
4
2
1
3
2
2
2

Supportive and Beneficial Providers. “I think all experiences have been positive
thus far [with healthcare providers]. Everyone seems either very knowledgeable, or they
defer to someone else who is better acquainted with BRCA.” Another commented that,
“Karen Brooks was amazing. She fully explained everything.”
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Table 2.10. Healthcare and support related to being BRCA1/2 positive.
Healthcare and Support (n = 115)
Providers made me feel supported through decision making
Empowered and supported my decision
Explained everything so I understood
Listened to my questions and concerns
Helpful
Empathy and compassion
Explained the science
Continued support over time / calls to see how I am doing
Phone number that I can call at any time
Respectful of what I did/did not know and explained when necessary
Persistence and will not give up trying to help
Being open with discussions
Made me feel in control over my medical decisions
Treated me like an adult
Feeling frustrated by healthcare providers
Unsympathetic or unsupportive care providers
Lack of BRCA knowledge
Having to advocate for own care / no one taking initiative
Lack of clarity about when surgeries can take place
Getting appropriate care during recovery from surgery
Not trying to find answers to questions asked
Not remembering who you are after repeat visits
Recommend seeing a genetic counselor
Supportive
Helpful and accurate information
Recommend genetic counseling before result disclosure
Recommend finding other young mutation carriers
Become part of the sisterhood to find others like you
You are never alone
Only positive experiences related to BRCA and clinical care
Genetic counselors provided no new information
Reviewed all options with a physician prior to genetic counseling
Already knew a lot about BRCA from family experience
Would not recommend or was frustrated by genetic counseling

n
61
10
9
9
8
6
4
4
3
2
2
2
1
1
16
6
3
2
2
1
1
1
14
6
4
4
10
7
3
8
6
2
2
2

Trouble Receiving Age-Appropriate Care from Providers.
- One oncologist I saw recommended that I see a therapist, after I came to
her office expressing concerns about changes in my body. I think she used
‘overreacting’ in the conversation, even though she knew my risk. It was
incredibly frustrating to see a doctor dismiss concerns, when so much of
surveillance is about doing self-breast exams and being aware of your own
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body. Many oncologists deal with older women who already have breast
cancer and really have no idea what it’s like to live with BRCA.
- A sonographer I recently encountered made it clear that she did not agree
with genetic testing or the use of surveillance techniques for BRCA+
carriers. It was a very awkward 20 minutes where I was interrogated until
she felt I had justified having an ultrasound.
Trouble Receiving Age-Appropriate Care from Genetic Counselors.
- It was basically useless. …They had no clue how to talk to someone
who wasn’t 40. They guy spent a bunch of time explaining what kind of
surgeon I needed to find to do my oopherectomy. Obviously, you need to
provide information about what kind of prevention to do down the line,
but they gave me really almost no sense of what I should be doing at 24. I
wouldn’t recommend genetic counseling to anyone.
- A second wrote: The only really bad experience I had was with a
genetics counselor. He was condescending and really seemed to have no
idea how to talk to me, or to formulate advice from someone in her midtwenties.
Recommend Genetic Counseling. Fourteen participants commented favorably on
genetic counseling and mentioned that they would recommend it to others. One wrote,
“Just having them spending the time addressing your questions and concerns. The most
important thing is to GET TO COUNSELING! This is a major decision mentally,
emotionally, and physically and you need to be prepared." For another, "The genetic
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counselor provided me the most helpful information and guidance in terms of risk
percentages, risk reduction methods, and a preventative plan of action."
- Definitely recommend genetic counseling with someone who specializes
in BRCA. There is so much misinformation on there and judgment from
people or medical professionals that aren’t really in the know. It's super
important to talk about your specific situation and not just go based off
general guidelines. There is no one size fits all when it comes to things
like this.
- It was refreshing to speak to someone who was both impartial without a
personal stance (that she demonstrated in her professional capacity at
least) and who did not require explanations but was able to provide them.
The information she provided was helpful for follow up conversations that
I had with my family physician regarding my screening and medical
decisions.
Genetic Counseling Provided no New Information.
- I did receive genetic counseling prior to my BRCA test. Because my
mother had tested positive a few years before and I had done a ton of
research. I knew most of what the CGC shared with me. None of it was
truly new information but I think genetic counseling is immensely
valuable for those who are not as aware of what it means to be BRCA
positive.
- I had known that I may have BRCA2 since I was ten years old and had
grown up discussing the issue with my mom, who had had breast cancer
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when she was 36. As a result, I didn’t get any new information from
genetic counseling.
- [A Genetic counselor] wanted to refer me for counselling as she felt ‘I
wasn’t coping with the death’ of my aunt (she dies from pancreatic cancer
with suspected link to the BRCA1 gene). My aunt had only died a month
prior to this session and I felt (and still feel) that I was coping well and
simply working my way through the grieving process.
Altered timeline for life. Participants indicated that they felt a need to speed up
(n = 40) or slow down (n = 6) their timeline for life events after learning that they carried
a BRCA1/2 gene mutation (Figure 2.4). Participants reported feeling like they had to
speed up having children (n = 18) or finding a husband (n = 9).
Life Timeline as Either Delayed or Rushed. One wrote, “It makes me fell like I
need to get married sooner and find a partner who would not mind if I have to have my
breasts and reproductive organs removed.”
- Although I have been married for over four years, my husband and I
have not immediate plans for children. My physicians have been
questioning if this is something we would want to consider more
immediately because of how it may affect future options. While I do not
want this to be the reason behind our family planning, I have found it to be
creating pressure to speed up our conversations and plans for the future.
Simultaneously, as we do not feel that we wish to start a family at this
point, I feel that the two feelings are creating tension.
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Had them faster (8)

Childern
(18)

Faster so ovaries can be
removed earlier (5)
Feel a need to have them faster
(5)
Looked for serious partners
only (2)

Husband/Partner
(9)
Faster
Timeline
for Life
(40)

Felt the need to marry more
quickly (3)
Now a big consideration
when planning life
(4)

Education
(7)

I thought it would at
first, but it has not (2)

Slower
Timeline
for Life
(6)

Got married quicker (4)

Altered educational path (4)

Planning when to complete
degree vs. when to have
surgeries or children (2)
Motivated to not delay
pursuing life goals (1) and
career (1)

Cancer diagnosis / delayed
wedding and having children
(1)
Underwent bilateral
mastectomy (2)
Prophylactic / delayed job
hunt and moving out of
parent's home (1)

Figure 2.4. Participants’ BRCA1/2 status as pressure to speed up or slow down life.
Delayed Timeline for Life.
- Testing positive didn’t affect the timeline for my life, however, my
cancer diagnosis did. I had to defer my education to undergo treatments
…children would have to wait a year after finishing chemotherapy to
ensure the drugs are out of my body.
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Different Pressure than Older BRCA Carriers Feel.
- It has affected my life timeline in terms of being more aware of decisions
I need to take…. as I am still very young, I don’t feel under pressure by
the remaining time that I have. (As opposed to women I have met who are
approaching 40, single, wanting to have children, but needing to remove
their ovaries soon). I hope I will not have to face these challenges.
Views on Family Planning Options. Participants mentioned or discussed family
planning options seventy-three times (n = 73). Participants were asked to describe what
they know or their thoughts on in-Vitro Fertilization (IVF), Preimplantation Genetic
Diagnosis (PGD), adoption, or surrogacy. Participants were asked if they were pursing
family planning yet or what they thought there future plans may look like (Figure 2.5).
Major themes included families being informed of PGD and IVF but not wanting
to use the technology (n = 17). Others had been informed about PGD and IVF and would
consider using it (n = 16). Other participants considered or planed to adopting in the
future (n = 13) or elected not to have children (n = 11).
Desire to Have Children the Natural Way. One wrote, “I still plan to get married
and having children. With the technology that has come out I can only hope my children
have the options plus more if they were faced with the BRCA gene.”
- I still want kids gene or no gene. I feel like it’s not fair that I shouldn’t
have kids or a family just because of the gene. I am just like everyone else
and there are tons of other people having kids with other genes and issues.
This is just my something and it shouldn’t stop me from leading a
fulfilling life.
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Prefer the natural way (11)

Informed of IVF/PGD:
Would not use it
(17)

Chilren the natural way: IVF and/or PGD
conflicts with personal beliefs (3)

PGD is unnecessary (1)

Not ready to think about family
planning at this stage in my life
(9)

High cost of PGD (2)

High cost of PGD (2)

Family
Planning
Options
(n = 73)

Informed of IVF/PGD:
Would consider using it
(16)

Would consider or plan to do in the future
(9) / Plan to freeze eggs (2)

Currently consulting providers about
family planning option (3)
Never informed (4) / Family is
complete (3)
Would consider or plan to do in the future (9)

Unable to have childern but want to add to
family (1)

Adoption
(13)

Desire for children has not changed, but
testing positive made adoption a more
attractive option (3)

No desire to have children (4)
No children
(11)

Unsure, but likly will not have children so the
mutation will not be passed on (7)

Figure 2.5. Participants’ opinions on family planning options.
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Would not use PGD. “It is expensive… PGD seems vaguely morally dubious.”
Another responded: I was advised of the option to use IVF to select
embryos without the mutation. This option goes a little too close to
playing with the powers of procreation for me.

…I know about my

mutation and can help my daughters and sons know if they have a
mutation as well and lead long healthy productive lives just like I am. I
don’t see it as a death sentence and don’t see like living a life with a
BRCA mutation would be unfair to them or to me.
High Cost of IVF and/or PGD. One replied, “If I am in a fortunate financial
position, I will consider PDG.” Another felt, “Pre-implantation for BRCA is silly, it is
not a childhood affecting disorder, it’s preventable 100% if you follow guidelines and
pay attention to your body. The IVF and other options are very nice, expensive but
interesting.” A third wrote, “I considered PGD. Then I discovered it costs 3-4 times as
much as regular IVF.”
Would Consider PDG. One explained that, “I have always wanted children. This
changes how I am going to go about making a family.”
- I’ve thought about adoption ONLY because I don’t know if I can have
kids. Seeing as how I have Endometriosis and miscarried several times,
not sure if my body can handle having my own kids. Of course I’ll try
IVF, but if that doesn’t work then I definitely want to adopt.
- A negative [of undergoing genetic testing] is that I ill consider in-vitro
fertilization and BRCA2 testing my embryos when I’m ready to have
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children. I never would’ve thought of reproduction so clinically before,
especially since I wouldn’t exist if my parents had that option.
Would Consider Adoption. For felt that, for her, “Whether they are of my womb
or adopted I will be there mother, there is no changing that.”
- PGD and IVF were presented to my husband and I, but because of our
values and beliefs we will not take part in any of those options. Adoption
is an option we have considered not only because of the positive BRCA1
results, but also because I may not be able to conceive after receiving
chemotherapy.
- As far as the future of my family goes, I never had a strong desire to
have children. As a carrier of this gene [mutation], I have less of a desire
to bear my own children. It has made me think differently about the idea
of adoption…or just having lots of awesome pets.
- I have never been very interested in having children, but having this gene
mutation that I could pass down to any offspring makes me not want to
have children. It almost makes me feel like it is my duty not to have
children, excluding the possibility of that life experience.
- When I first got my BRCA results, I wanted to have kids before age 30,
because experts say it reduces BC [breast cancer] risk. Now that I’ve had
cancer, though, I’m not sure I want to have kids at all. I have a 50%
chance of passing on the on and I’m not sure I want to do that and risk a
child of mine going through cancer like I did.
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2.5 Discussion
2.5.1 Participants.
Despite efforts to obtain a more diverse study sample in terms of sex,
race/ethnicity, education and income, the participant demographics in this study were
quite similar to the demographics achieved in related studies (Hoskins & Werner-Lin,
2012; Werner-Lin et al., 2012). Lack of variability in terms of race or ethnicity, despite
efforts to reach out to race or ethnicity-specific BRCA Facebook groups, was not ideal
yet not unexpected. Typically, African Americans as well as other minority groups are
hesitant to take part in research (Sherman, Miller, Shaw, Cavanagh & Sheinfield-Gorin,
2014). However, the study expanded to other countries outside of the United States and
reached a large number of participants. Therefore, one of the key aims to increase
sample size was achieved.
2.5.2. Satisfaction. We hypothesized that individuals who obtained their positive
genetic test result by age 25 would be satisfied with their decision to undergo genetic
testing, but somewhat less satisfied then those who were older than age 25 at the time of
the study. This was predicted since young mutation carriers are less familiar with making
autonomous decisions (Arnett, 2000) and have less mental capacity to examine each facet
and consequence of the decisions at hand (Ford et al., 1998; Steinberg, 2005). We found
that all participants, regardless of age, were highly satisfied with their decision to
undergo genetic testing. Thus, age did not have an effect on testing satisfaction as we
anticipated. This was consistent with previous data collected (Klemp et al., 2005). This
trend could be due to the fact that knowing in advance enabled young BRCA1/2 mutation
carriers time to plan for the future and develop an optimistic view for the future and

54

future research (Donnelly et al., 2013). For a number of participants, knowing their
BRCA1/2 mutation status did bring them optimism and hope for the future (n = 29) and
enabled them to regain their sense of control over cancer (n =5).
2.5.3. Recommendations for care providers and genetic professionals. While every
patient will be different and guide the way their care is provided, based on the data we
collected, there are five recommendations we propose to guide counseling for BRCA1/2
carriers under the age of 25. Care provision recommendations for young BRCA1/2
carriers include the five Rs.


Right Reproductive Organs: Discuss which female reproductive organs are
and are not at risk (i.e., NOT cervical cancer)



Risk Reducing Mastectomy: Primarily discuss prophylactic bilateral
mastectomy, with less time devoted to discussing oopherectomy



Risk Figures: Discuss age-specific risk figures and how lifetime empiric
cancer risk figures are accurate for them, and hopefully we will have even
more mutation-specific numbers in future
(i.e., most BRCA1/2 positive women have a significant cancer family
history)



Reproductive Options: Cover possible reproductive options
(Not all pregnancies are planned and basic knowledge can be important for
future or financial planning)



Resource for Future: Be an educated future resource
(Their needs and questions will change over time; be there to answer them.)
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These guidelines could benefit any health care professionals who work with
mutation carriers under age 25. However, both data from this study (n = 23) and previous
research (Hoskins et al., 2014; Ormondroyd et al., 2012) emphasize the need for trained
genetics professionals, such as genetic counselors, who fully understand BRCA. Similar
to Hoskins et al., BRCA1/2 carriers under age 25 in this study placed value providers who
made them feel empowered (n = 10), had clear explanations (n = 9), listened to their
questions (n = 9), were empathic (n = 6), explained the science (n = 4), and treated them
like adults (n = 1) (2014). Participants expressed frustration when healthcare providers
were unsupportive (n = 6) or lacked knowledge about BRCA (n = 3) and the surgery
guidelines (n = 2). These findings emphasized the need for better care and more
appropriate referrals to genetic professionals for mutation positive emerging adults.
While genetic professionals were reported to provide excellent guidance and care
(n = 14), assuring that the care provided is relevant for this age group is critical and one
of the bases for our recommendations presented. The topic of relevant care for women
under age 25 is two-fold. First, our study identified a need for clear guidelines regarding
screening and surgery. Conflicts regarding the best care strategies for BRCA1/2 positive
women under the age of 25 emerged from the data (n = 12). This confirmed what
previous researchers found (Hoskins et al., 2014). We found participants were using
over 16 different types and combinations of screening strategies. This lack of uniformity
regarding a surveillance protocol again supports the idea that a set guideline is necessary
in providing adequate care for those under age 25.
Second, our study identified a need for a unique counseling and care strategy for
young mutation carriers. Participants wrote that providers were misinformed or
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unfamiliar with BRCA (n = 4) and that genetic counselors specifically did not know what
types of recommendations are fitting for such young carriers (n = 3). This led to
participant frustration with genetics professionals who provided them no new information
related to BRCA (n = 6). This data indicated that future steps are necessary to assure
BRCA1/2 positive emerging adults are receiving care that is relevant at their young age.
Right Reproductive Organs. The data showed that participants had many
misconceptions regarding both surgeries and screening related to BRCA1/2. This is
consistent with previous literature (Patenaude et al., 2013). Of primary concern were
women discussing cervical cancer, which is a type of cancer unrelated to BRCA1/2 gene
mutations (Clark & Domchek, 2011). Participants expressed concerns about cervical
cancer in their family history (n = 2) or personal history (n = 1) and that they were
utilizing Pap smears as screening for ovarian cancer (n = 4). This was consistent with
pervious works that found young daughters of known BRCA1/2 mutation carriers also
mentioned the need for increased pap smears and worry over cervical cancer risk
(Patenaude et al., 2013).
One participant in particular noted that her motivation for undergoing
prophylactic bilateral oopherectomy, besides being BRCA positive, was because she had
cervical dysplasia and had never had a normal pap smear. An additional participant
expressed the need for early colonoscopies as well, which is yet another cancer not
typically associated with BRCA1/2 gene mutations (Clark & Domchek, 2011). There
needs to be increased patient education in this area. It is unacceptable that women may
be making life-altering or life-risking choices based on inaccurate information
surrounding topics such as cervical cancer risk.
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Other participant misconceptions centered on the topic of prophylactic surgery.
Eleven participants noted that they either had or planned to have hysterectomy or
specifically their uterus removed. Most did not mention the need for ovary removal.
This finding could have been because they simply failed to mention that their ovaries and
fallopian tubes were removed or that they intended to have them removed along with
their uterus. However, it is still concerning that participants are unfamiliar with the
correct surgical terms given that they will likely have or already have had surgeries.
Some participants specifically mentioned that they were to have their uterus
removed related to their BRCA1/2 positive status. While there may be a slight increased
risk for uterine cancer with BRCA1 mutation carriers in particular, the key reproductive
organs at highest risk for cancer are still the unmentioned ovaries and fallopian tubes
(Segev et al., 2013). Another participant expressed that she hoped to have only her
fallopian tubes removed and not her ovaries, despite the fact that the greatest risk for
ovarian cancer (Clark & Domchek, 2011).
Another responded that having an oopherectomy was not an option until after age
45, despite the fact that she personally desired it sooner. This is an unfortunate
misconception, not only since patients should be able to receive the treatments they desire
but also because guidelines state that oopherectomy should be considered as early as ages
35 to 40 (Berliner et al., 2013; Clark & Domchek, 2011). This was a new finding related
to young BRCA1/2 carriers. These results clearly demonstrate a need for future education
of very young BRCA1/2 mutation carriers’ pertaining to the risks specific to each female
reproductive organ.
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Risk Reducing Mastectomy. The data showed that all of the women who took
part in this study (N = 63) had considered prophylactic surgery. The main topic
participants discussed was mastectomy (n = 128), signifying that this is a critical topic
for these very young mutation carriers. Surgery related to the ovaries or uterus was
referenced less often (n = 72) with over half of the references having to do with
participants wanting to wait until after they have children or were past age 30 (n = 47).
This indicated that, while the topic of oopherectomy is important to be aware of and plan
for in the future for these young carriers, it is not of main concern nor will they desire
oopherectomy in the near future. Thus, young carriers only need to receive counseling
and guidance regarding the salient related to oopherectomy at this age.
Healthcare providers must keep in mind that, unlike older BRCA1/2 mutation
carriers, emerging adults have more time to contemplate their screening and surgery
options. Carefully attention is needed when providing care for BRCA1/2 positive
emerging adults to assure their autonomy and full understanding of surgical choices
(Arnett, 2000; Werner-Lin et al., 2012). Given the almost non-existent risk of ovarian
cancer prior to age 30 (Stratton et al., 1999), the topic of oopherectomy is better saved for
future healthcare appointments or sessions. The topic of prophylactic mastectomy, on the
other hand, is critical.
Risk Figures. We found that many women either overestimated their cancer risk
(n = 16) or quoted accurate numbers but said that they believe their actual risk for cancer
is much higher because of their family history (n = 16). We also found that women often
overestimated their risk for cancer at their current age, thinking that their current risk for
cancer was more similar to the lifetime risks. This overestimation of risk was supported
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findings from previous work (Patenaude et al., 2013; Werner-Lin, 2007). Thus, two
recommendations were made regarding how risk figures should be discussed with BRCA
positive emerging adults. First, review their current age related risk for both breast and
ovarian cancer. The likelihood for cancer between the ages of 20 and 24 is very low, and
patients need to know and understand this data. It is estimated the BRCA1/2 carriers have
a 0.02% for breast cancer and .001% for ovarian cancer (Antoniou, et al., 2003).
However, none of the respondents quoted or mentioned that their current risk for cancer
was this low. Thus, this suggests that participants are not being well informed about their
risk for cancer diagnosis specific to their young age.
Second, participants need to be reminded that their lifetime risk for cancer is most
accurately represented by empiric risk data for BRAC1/2 mutation carriers. Family
history does play an important role in determining who receives genetic testing and who
seeks genetic testing. However, once a person is a known carrier, there are cancer risk
estimates available for BRCA1 or BRCA2. At this point, patients need to be reminded
that, typically, family history does not elevate their risk to be higher than published data.
It would be unusual to find a BRCA1/2 mutation carrier that did not have a substantial
family history of cancer due to the automsomal dominant nature of HBOC syndrome and
the fact that de novo cases are very rare (Clark & Domchek, 2011). Most participants in
our study cited extensive family histories of cancer (n = 64).
Common misconceptions included responses such as, “95% because both my
grandmothers had breast cancer and my mother had both breast and ovarian cancer and
now that I know I have a BRCA1 gene mutation I know my risk is vary high” or “I had a
98% chance by age 30, it wasn’t an option to not be preventative [and undergo
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mastectomy].” Based on this data, we propose that time needs to be spent focusing on
known risk numbers and reminding patients that most fellow-carriers have an extensive
family history of cancer experiences. An extensive cancer family history does not make
the likelihood of cancer absolute (Werner-Lin, 2007).
These are recommendations, and with recommendations there always come
exceptions. Thus, it is recommended providers inform patients that we may learn more
about more mutation-specific risks in the future. HBOC is a cancer predisposition
syndrome and not an absolute cancer-causing disease. Over time, there is hope that we
may learn genotype-phenotype correlations do exist and that mutation-specific risk
estimates may become available (Donnelly et al., 2013). At the current time, it is our
recommendation that providers offer the most up-to-data risk estimate data both for a
patient’s current age and for over their lifetime, while encouraging patients to stay in
touch as new data emerges in the future.
Reproductive Options. A large number of participants expressed their thoughts
on reproductive issues and family planning (n = 73). Based on the volume of responses
related to reproduction, we concluded that reproductive issues and family planning are
highly relevant topic for young mutation carriers. Healthcare providers working with
young BRCA carriers will need to assure that they are prepared to discuss these variable
topics. This supported the conclusion from previous work with young BRCA1/2 carriers
(Ormondroyd et al., 2012).
A minority of written responses referenced participants not yet being ready to
think about family planning at their current life stage. A majority discussed their
thoughts on adoption, IVF with or without PGD, having a family the natural way, or that
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they desired no children. Many noted that they had at least considered these options and
that their desires related to family planning have evolved over time. This data proved
that these options are of importance to most women in this age group. Even if they are
not ready at the current time to utilize these options, they are apart of most participants’
life plans. Based on our data, and the fact that not all pregnancies are planned, we
recommend that family planning options are presented to patients. From their, patients
can guide to what level of detail each option is discussed, if it at all at the current time.
This way the seed is planted so that, in the future, education discussions can take place as
the needs of young BRCA carriers evolve.
As anticipated, we also saw participants express that they struggled to find a
balance between reducing risk and losing reproductive options (Werner-Lin, 2008). A
common trend was planning to delay having surgeries so that they could have a family (n
= 29). For most, oopherectomy only was postponed until childbearing was complete.
However, participants also brought up the desire to breastfeed their children as a primary
reason for why they desired to delay having both mastectomy and oopherectomy. Due to
the variability in participant responses and desires, careful and unbiased counseling
where these young carriers feel supported in their decisions will be essential to enabling
full patient autonomy (Hoskins et al., 2014), as found by previous researchers as well as
our study.
Resource for Future. Needs of emerging adults change over time (Arnett, 2000)
and thus, so do their needs concerning cancer risk management (Hoskins et al., 2014).
We propose that health care providers or genetic counselor that work with these BRCA1/2
positive emerging adults inform these young carriers that care will extend beyond the
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first appointment. Young BRCA carriers who that they are positive prior to age 25 stated
that their medical management needs and questions will change over time. This could
range anywhere from talking about birth control as their current mode of family planning
to discussing the need to plan financially for IVF with or without PGD.
There are no one-size fits all plans. Providing young BRCA carriers the
knowledge that they always will have a healthcare or genetics professional available to
answer important questions that may arise is key. Young carriers felt the most pleased
with their care when they are supported and guided through and beyond emerging
adulthood (Arnett, 2000; Hoskins et al., 2012; Hoskins et al., 2014).
2.5.4. Limitations. Individuals were recruited via the Internet, limiting the study to
individuals with Internet access that periodically visit BRCA-related websites or follow
social media accounts. Participation in this study was not limited to women only.
However, the websites and social media used to gather participants primarily cater to a
female audience. Since HBOC syndrome affects primarily women, it is typical to obtain
few to no male participants in BRCA research. In addition, we did not obtain an
ethnically and socioeconomically diverse sample. Thus, findings may not generalize
across ethnic groups, to people of different socioeconomic status, or across disease types.
2.5.5. Areas for Future Research. Future research opportunities identified through the
course of this study, which could use additional study, are listed below.


Targeting male participants and minority groups
o Resources are men or minority groups using as a source of support
and guidance, so they can used in future research efforts
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o What these groups’ knowledge is concerning their reproductive
health and personal cancer risk


Additional studies focusing on how this group is undergoing surveillance or
planning for surgeries, since we saw significant inconsistencies in their
established healthcare plans



Expanding beyond HBOC to determine the counseling needs for different
caner disposition syndromes (Cowden syndrome, Lynch Syndrome, etc.)

Beyond BRCA, there is much research that needs to be done on mutation carriers
under the age of 25, but with other hereditary cancer predisposition syndromes. There
are more young individuals living everyday life knowing that their risk for cancers is
significantly higher then that of the general population, without guidelines to inform them
how they should be undergoing surveillance (Clark & Domchek, 2011).
2.6 Conclusions
Our study followed in the path of previous, related works on BRCA1/2 positive
emerging adults. We found that participants were very satisfied with their decision to
undergo genetic testing, with satisfaction scores of 4.7 out of 5. Satisfaction was high
regardless of age, life stability, or whether or not they had received genetic counseling.
Much like these previous studies, our research found a lack of guidance, support, and
consistent standard of care for mutation carriers who received genetic testing before age
25 (Hoskins & Werner-Lin, 2012; Hoskins et al, 2014). Our study was unique in the fact
that we were successful in gathering information from a larger participant pool (N =63).
Based on the data obtained, five suggestions were developed to guide health care
providers and genetic professionals to better care for BRCA1/2 positive emerging adults.
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Recommendations, or the five Rs included: (1) Reproductive Organs: Discuss which
female reproductive organs are and are not at risk (i.e. NOT cervical cancer); (2) Risk
Reducing Mastectomy: Primarily discuss prophylactic bilateral mastectomy, with less
time devoted to discussing oopherectomy; (3) Risk Figures: Discuss age-specific risk
figures and how lifetime empiric cancer risk figures are accurate for them, and hopefully
we will have even more mutation-specific numbers in future (i.e., most BRCA1/2 positive
women have a significant cancer family history); (4) Reproductive Options: Cover
possible reproductive options (not all pregnancies are planned; basic knowledge can be
critical for future or financial planning); and (5) Resource for Future: Be an educated
future resource (Their needs and questions will change over time, be there to answer
them).
Participants in this emerging adult group were variable in their responses, desires,
and medical management plans for the future. A clear trend was that participants desired
more clear and unbiased care and counseling, where they felt supported. The complexity
of HBOC plus the variable lives BRCA1/2 positive emerging adults face led us to propose
a core set of counseling recommendations for young BRCA mutation carriers under age
25. Incorporating the five recommendations is essential to achieving full patient
autonomy and unbiased decision facilitation.
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Chapter 3. Conclusions
Our study followed in the path of previous, related works on BRCA1/2 positive
emerging adults. Much like these previous studies, our research found a lack of
guidance, support, and consistent standard of care for mutation carriers who received
genetic testing before age 25 (Hoskins & Werner-Lin, 2012; Hoskins et al., 2014). Our
study was unique in the fact that we were successful in gathering information from a
larger participant pool (N =63) that was more geographically diverse. We found that
participants were very satisfied with their decision to undergo genetic testing, with
satisfaction scores of 4.7 out of 5. Satisfaction was high regardless of age, life stability,
or whether or not they had received genetic counseling.
Based on the data obtained, five suggestions were developed to guide health care
providers and genetic professionals to better care for BRCA1/2 positive emerging adults.
Recommendations, or the five Rs included: (1) Right Reproductive Organs: Discuss
which female reproductive organs are and are not at risk (i.e. NOT cervical cancer), (2)
Risk Reducing Mastectomy: Primarily discuss prophylactic bilateral mastectomy, with
less time devoted to discussing oopherectomy, (3) Risk Figures: Discuss age-specific risk
figures and how lifetime empiric cancer risk figures are accurate for them, and hopefully
we will have even more mutation-specific numbers in future (i.e. most BRCA1/2 positive
women have a significant cancer family history), (4) Reproductive Options: Cover
possible reproductive options (Not all pregnancies are planned and basic knowledge can
be critical for future or financial planning) (5) Resource for Future: Be an educated
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future resource (Their needs and questions will change over time, be there to answer
them).
Participants in this emerging adult group were variable in their responses, desires,
and medical management plans for the future. A clear trend was that participants desired
more clear and unbiased care and counseling, where they felt supported. The complexity
of HBOC plus the variable lives BRCA1/2 positive emerging adults face led us to propose
a core set of counseling recommendations for young BRCA mutation carriers under age
25. Incorporating the five recommendations is essential to achieving full patient
autonomy and unbiased decision facilitation.
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Appendix A: List of Social Media Sources Contacted and/or Utilized
Facebook
African American Breast Cancer Research Study

Just Ask! About Hereditary Breast and Ovarian Cancer
(HBOC)

BRCA1

LA FORCE: Facing Our Risk Empowered

BRCA1 or BRCA2 Genetic Ovarian & Breast Cancer Gene

Let’s Free Our BRCA Data!!

BRCA1/BRCA2+ UK

Male Breast Cancer

BRCA Advanced 101 & 102

Male Breast Cancer Awareness

BRCA Brotherhood

Men Against Breast Cancer

BRCA Commons

Power of Pink! Foundation

BRCA Sisterhood

P.O.P.! Power of Pink Foundation

BRCA Sisterhood Canada

SHARE Cancer Support

BRCA Umbrella - The Breast & Ovarian Cancer Gene & You

Sisters Network Inc.

BRCA Gene Awareness Inc.

The Breast Cancer Site

Breast Cancer Campaign

Think Pink Rocks

BRCA Gene Awareness, Inc.

Ulman Cancer Fund for Young Adults

FAMILIES WHO SUPPORT BREAST CANCER SURVIVORS, Inc.

Ulman Cancer Fund’s TEAM FIGHT

FORCE: Facing Our Risk of Cancer Empowered

Young Previvors

Hereditary Breast & Ovarian Cancer (HBOC) Montreal

Young Survival Coalition Bulletin Board
Young Women's Breast Cancer Awareness Foundation
(YWBCAF)

HBOC Society
Imerman Angels
Blogs
BRCA According to Me (ponderingprevivor.blogspot.com)
BRCA Blog Directory (brcablogdirectory.wordpress.com)
BRCA Sisterhood Blog (brcasisterhood.wordpress.com/the-sisterhood)
Breaking BRCA (brcaprevivor.blogspot.com)
Fitting into my BRCA Genes (fittingintomygenes.blogspot.com)
My BRCA Blog (brcaandme.blogspot.com)
My Journey With BRCA1 (brca1journey.blogspot.com)

Previving and Thriving: My BRCA2+ Journey (previvingandthriving.com)
PREvivor GENEration (previvorgeneration.com)
Staying Positive, BRCA Positive (stayingpositivebrca.blogspot.com)
Wearing My BRCA Genes (youngbrca1.wordpress.com)
Young and BRCA1 Positive and High Heals: Making Our Genes Look Good (youngbrca1pos.blogspot.com)
Other
Bright Pink (Twitter) (@BeBrightPink)

HBOC Society (Newsletter)

FORCE: Facing Our Risk of Cancer Empowered (Message Boards)
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Appendix B: Templates for Correspondence with Social Media Groups
Email Request for Hosting Research Survey
To Whom It May Concern:
Hello, my name is Sarah King and I am a second year genetic counseling student at the
University of South Carolina. My graduate student thesis project is on unaffected
BRCA1 and BRCA2 gene mutation carriers under the age of 25. The goal is to see how
age affects the risk perception and life choices of these young individuals. This data will
be collected via an online survey through Survey Monkey.com. I would love to
potentially work with your organization to attempt to reach this population of individuals
for my study.
So you all are aware, this thesis project will undergo IRB approval though the University
of South Carolina and poses virtually no harm or risk to participants. In addition, I plan
publish my research once the project is complete to help more individuals in this young
age group in the future.
Reaching enough individuals in this specific age group will be key to obtaining
statistically significant results. I think there is a great need for more information, since
there is minimal literature, guidelines, or recommendations written for this age group.
Therefore, I would sincerely appreciate your support.
What I am hoping is that a letter to potential participants as well as the link to my survey
be posted somewhere online. This could include your website, face book page, etc.
Wherever you think it would be best would be much appreciated.
If you would like to me to call you to discuss my project, or if you need further
information I would be more then happy to provide that for you. I have a tentative
written thesis proposal as well as rough drafts of all survey questions if you would like to
look them over.
Thank you so much for your consideration and I look forward to your reply,
Sarah King
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Social Media Templates Inviting Participants with Survey Link: Twitter
Original Post:

Updated Post:
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Forum Post for FORCE Website
Hello ladies and possibly some gentleman out there as well I would like to invite you to take part in a graduate research study looking at BRCA1 and
BRCA2 mutation carriers that are 18 to 24 years old. I am a graduate student in the
genetic counseling program at the University of South Carolina School of Medicine. My
study looks at the affect of age on life choices and satisfaction with the choice to have
genetic testing for young people in this age group.
To take part in the study, you would need to fill-out a survey on the choices that you have
made, your overall satisfaction with your choice to have genetic testing, and resources
that you use for support. You are eligible for this study if you are 18 to 24 years old and
have had genetic testing where you tested positive for a BRCA1 or BRCA2 gene
mutation. Both men and women are welcome to take part! I encourage you all to share
your stories as much as possible.
The survey looks at themes in the life choices and decisions of individuals in this young
age group. If you do not wish to answer a question, please skip that question and
continue filling out the rest of the survey. The survey is 40 questions in length,
including the questions pertaining to demographics such as age or education level. To
participate in this research please click here or follow this link:
http://www.surveymonkey.com/s/8HQNVDD
All responses from the surveys will be kept anonymous and confidential. We only ask
for your name and phone number in case you would be interested in providing more
information at a later date over the phone. It is not necessary that you provide this
information. The results of this study might be published or presented at academic
meetings; however, participants will not be identified. Your contact information will not
be used for any other purposes besides a follow-up phone interview.
Your participation in this study is voluntary. By completing the study, you are stating that
you have read and understand this information. At any time, you may withdraw from the
study by not finishing filling out the survey.
Thank you for your time and consideration. Your responses may help health care
providers such as genetic counselors better care for young, high-risk people 18 to 24
years of age in the future. If you have any questions about this study, you may contact
either myself or my faculty adviser, Karen Brooks, MS, CGC, using the contact
information below. If you have any questions about your rights as a study or research
participant, you may contact the Office of Research Compliance at the University of
South Carolina at (803)777-7095.
Thank you all for your time and support!
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Sarah
Sarah E. King, B.A.
Genetic Counselor Candidate
sarah.elaine.king@gmail.com
(260) 367-1889
Karen Brooks, MS, CGC
Faculty Adviser
Karen.Brooks@uscmed.sc.edu
(803) 545-5746
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Facebook Message for Direct Message
Hello, my name is Sarah King and I am a second year genetic counseling student at the
University of South Carolina in the US. My graduate student thesis project is on BRCA1
and BRCA2 gene mutation carriers who tested positive for a BRCA1/2 gene mutation
before the age of 25.
The goal is to see how age affects the risk perception and life choices of these young
individuals. This data will be collected via an online survey through
SurveyMonkey.com. I would love to potentially work with your organization to attempt
to reach this population of individuals for my study.
So you all are aware, this thesis project will undergo IRB approval though the University
of South Carolina and poses virtually no harm or risk to participants. In addition, I plan
publish my research once the project is complete to help more individuals in this young
age group in the future.
Reaching enough individuals in this specific age group will be key to obtaining
statistically significant results. I think there is a great need for more information, since
there is minimal literature, guidelines, or recommendations written for this age group.
Therefore, I would sincerely appreciate your support.
What I am hoping is that a link to my survey be posted somewhere online. This could
include your website, Facebook page, Twitter account, etc. Wherever you think it would
be best would be much appreciated. I have included sample Facebook and Twitter posts
for you.
Also, I am not sure if this was the best way to get in contact with your organization, but I
believe it will be a good starting point.
Thank you so much for your consideration and I look forward to your reply,
Sarah King
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Facebook Message for Facebook Wall
HelloMy name is Sarah and I am a second year genetic counseling student from South
Carolina. I have a special interest in women or men who are young survivors/previvors. I
am working on my graduate thesis and am trying to gain as much information about
young previvors and their hopes/plans/experiences/etc. I hope you would not mind if I
posted the link for my study. Thanks for your consideration!
Also -Some of you may have already seen the link to my study-- It was tweeted by Bright
Pink recently!
Study Information:
Help future young, high-risk individuals like you by participating in a research study. We
would love to hear your personal story!
We are looking for women or men who discovered that they are BRCA1 or BRCA2
mutation positive before the age of 25 to take our online survey! You qualify for the
study if you had genetic testing before your 25th birthday and tested positive. For more
details and information or to participate in our research please click here:
http://www.surveymonkey.com/s/8HQNVDD
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Social Media Templates Inviting Participants with Survey Link: Facebook
Original Post:
Help future young, high-risk individuals like you by participating in a research study. We
would love to hear your personal story!
We are looking for women or men under the age of 25 who have undergone genetic
testing and know that they carry a BRCA1 or BRCA2 gene mutation to take our online
survey! For more details and information or to participate in our research please click
here:http://www.surveymonkey.com/s/8HQNVDD
Thank you all very much for you time, support, and consideration!
Updated Post:
Help future young, high-risk individuals like you by participating in a research study.
We would love to hear your personal story!
We are looking for women or men who discovered that they are BRCA1 or BRCA2
mutation positive before the age of 25 to take our online survey! You qualify for the
study if you had genetic testing before your 25th birthday and tested positive. For more
details and information or to participate in our research please click here:
http://www.surveymonkey.com/s/8HQNVDD
Thank you all very much for you time, support, and consideration!
Study Update Post:
We would like to expand this study to anyone who found out that they are BRCA1 or
BRCA2 positive before the age of 25. You qualify for the study if had genetic testing
before your 25th birthday and tested positive.
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Formal Survey Invitation to Participants
Dear Potential Participant:
You are invited to take part in a graduate research study looking at BRCA1 and BRCA2
mutation carriers that received a positive BRCA1/2 genetic test result when they were
under the age of 25. I am a graduate student in the genetic counseling program at the
University of South Carolina School of Medicine. My study looks at the affect of age on
life choices and satisfaction with the choice to have genetic testing for young people in
this age group.
To take part in the study, you would need to fill-out a survey on the choices that you have
made, your overall satisfaction with your choice to have genetic testing, and resources
that you use for support. You are eligible for this study if you were under 25 years of age
when you had testing and if you tested positive for a BRCA1 or BRCA2 gene mutation.
Both men and women are encouraged to take part!
The survey looks at themes in the life choices and decisions of individuals in this young
age group. If you do not wish to answer a question, please skip that question and continue
filling out the rest of the survey. The survey is 40 questions in length, including the
questions pertaining to demographics such as age or education level. We would love to
hear your story!
All responses from the surveys will be kept anonymous and confidential. We only ask for
your name and phone number in case you would be interested in providing more
information at a later date over the phone. It is not necessary that you provide this
information. The results of this study might be published or presented at academic
meetings; however, participants will not be identified. Your contact information will not
be used for any other purposes besides a follow-up phone interview.
Your participation in this study is voluntary. By completing the study, you are stating that
you have read and understand this information. At any time, you may withdraw from the
study by not finishing filling out the survey.
Thank you for your time and consideration. Your responses may help health care
providers such as genetic counselors better care for young, high-risk people 18 to 24
years of age in the future. If you have any questions about this study, you may contact
either myself or my faculty adviser, Karen Brooks, MS, CGC, using the contact
information below. If you have any questions about your rights as a study or research
participant, you may contact the Office of Research Compliance at the University of
South Carolina at (803)777-7095.
Sincerely,
Sarah E. King, B.A.
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Genetic Counselor Candidate
University of South Carolina School of Medicine
USC Genetic Counseling Program
Two Medical Park, Suite 208
Columbia, SC 29203
sarah.elaine.king@gmail.com
(260) 367-1889
Karen Brooks, MS, CGC
Faculty Adviser
University of South Carolina School of Medicine
USC Genetic Counseling Program
Two Medical Park, Suite 208
Columbia, SC 29203
Karen.Brooks@uscmed.sc.edu
(803) 545-5746
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Appendix C: Participant Survey
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Appendix D: Advice from one BRCA1/2 Positive Women to Another
Advice from one Young, BRCA1/2 Positive Woman to Another
I think it is amazing that you can find out. It is stressful but a blessing to know. I would hate to not know and have to
go through cancer treatments. If you know, you can plan ahead.
It's better to know. Then you can help prevent.
Befriend your oncologist, hematologist, and your obgyn oncologist. They are your guides on this journey. Research
options and ask the doctors many questions. Ask them if they were in your shoes, what would they do.
You don't need to act on the results right away. You can do surveillance but it gets exhausting and the anxiety may
get to you- it did for me. You can do the PBM before having children...I felt rushed to have kids and them I did my
surgery but may have done it before in hindsight.
I would tell them that knowing is a gift. If you have the mutation, you're probably going to find out at some point
anyway. This way it doesn't creep up on you in the prime of your life, and you have options to massively reduce
your risk. It's going to be scary and frustrating, and if it's positive your life and even your identity will change. Also,
good luck.
It's better to know, because it gives you the power to make healthy choices for yourself and your future. Why let
yourself be blindsided down the road when you can have the comfort of knowing you are doing all the best you can
for yourself?
It depends on the person.
Just take it a day at a time. Find a support group that works for you. I have a few on Facebook that have truly
brought me through all of this. You don't have to be alone, and you aren't. It is hard for friends and family who are
not going through it to always understand, so having a group of people who do is major. Also, research, research,
research. You need to be your own advocate, and often times you will find yourself educating the health care
providers. The more you know, the easier it will be!
Don't fret. It's truly not the end of the world. Think of it as a Godsend because if you DO test positive just remember
it doesn't mean you will end up with cancer. And if you do end up with it, you'll have caught it early enough so there
won't be much of a problem. Just try to relax, and don't freak out.
I would tell her to make sure she's really ready for what a positive result means. A lot of people test so they can hear
it's negative.
Whether it is positive or negative, it is good news. The knowledge gives you amazing power.
Surround yourself with good literature, good people and supportive environment, be true to you, and find out your
values, know that it's ok to be scared of the unknown. Don't take no for an answer, you know your body... Better
than any dr
Just as much info as possible, so they can go in armed with questions if need be.
It’s not the end of the world and make sure that you know surgery is not the only option it was the only option i was
given and I would have tried preventative drugs had i known about them,
I would recommend the FORCE website.
Think about what you will do with the information when you get it
My decisions have always boiled down to: why not now? Is there a reason I should wait until I'm older to get a
procedure done? You need to take everything into account when answering those questions. It's not just about the
procedure themselves, but also very much where you are in your life at this moment and where you'd like to be in
the immediate future. I was in an 'in-between' moment in my life. I had just ended a big part of my life and hadn't
yet started something new. Don't feel rushed. Find the right moment.
That there is pros and cons to being positive or negative. You can't listen to what you’re being told is your right
option because it is your body, your right and your decision. You also can't let it control your life but now you have
to live life to the fullest.
You are not defined by your genes! Find your community and start learning the stories of others who have been
through this (I tend to trust FORCE more than I trust Bright Pink). There are some incredible online communities
out there that can support you and answer your questions. Here is one of them:
https://www.facebook.com/groups/bravebosom/
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No matter what the result is, it is not a death sentence - it's a blessing. This test gives you your power back. Power
over your health, the power to make decisions, the power to DECIDE how to live your best life. This test doesn't
change anything about your health - if you have a mutation, it has been there since the moment you were conceived.
BUT, this test DOES change what you can do about it. IF you have a mutation, you get to DECIDE how it will
impact your life. You get to protect yourself and your health.
I would say that everyone is different, but in my opinion, it is better to know either way so that you can better
prepare for your future instead of wondering and not taking the proper preventative actions, which would only put
him/her at a higher risk of developing cancer. It is best to know so that you know what to do about it.
It's not really so big a deal. The risk of getting cancer is high for everyone, but if you get a positive result at least
you will be studied regularly. Also mastectomy is not as bad as it might seem, at least I am very happy of my
decision.
Don’t take this as an end to your life look at it as a wake up call and do what you want to do and what you feel is
right for you
Knowledge is power and finding out one way or another is a positive and brave thing to do. You are taking control
of your future and you can decide what you want to do going forward. If you do test positive for a faulty gene, do
not rush in to making any decisions about preventative surgery. If you do decide to undergo preventative surgery, do
as much research as possible before seeing a surgeon.
Don't feel pressurized by the media or medical professionals into making massive decisions about your body. Only
you, with support from your nearest and dearest, can decide what is right for you.
No matter what the result is you may still get cancer or you may never get cancer. Look at the result as a tool to
leading a healthier life. If it is positive, it really is so much better to know so if you ever do get cancer it can be
caught at an early stage
That person would strongly benefit from a little company & probably some healthy distractions. Jumping into
education regarding their options would only overwhelm them in the meanwhile.
Not to worry, and to only see a positive test as knowing as early as possible so you can get on the track to being
aware of the risks
One day at a time
I would tell them that they will be the same person after their results as they are before and their beliefs and
priorities should stay pretty much the same. The timeline of your life and the things you need to do to stay healthy
may change, but your life is no less beautiful after the results than before. And knowing about a mutation is actually
a beautiful gift because it changes you into a proactive person who can have a dramatic impact on your own future
instead of just waiting around and wondering. It helps you make the most of your life in a way that most people
can't.
No matter your result, you are healthy. I have found this to be an important thought to return to as the screening
process, the options, and the risks laid out can easily paint a picture and feeling of a health crisis. Having a support
network is very important, as is being able to take time for yourself away from the business, the tests, and sometimes
other people, as you need.
I would say to just take the first month or two and let the results sink in. You will feel a lot of feelings and be very
overwhelmed for a while, but don't make any decisions right then because you won't have enough distance to be
objective. Once the dust settles, then you should really start researching your options. Go to a conference (like the
Facing Our Risk of Cancer Empowered conference), reach out to support groups to talk to other women, and talk to
a lot of doctors. You may not feel like you have time, but you also shouldn't make any decisions without being
completely informed first.
I recommend that everyone at genetic risk for HBOC meet with a genetic counselor, develop a family tree, and a list
of family cancers and the ages diagnosed. I also recommend that they hear the results in person, not over the phone
or via mail as I've heard some folks have.
That everything will be ok and that even though positive result sucks and will probably turn your life upside down,
it's wonderful that this option is available. Being able to take preventative measures is better than having to fight
cancer and possibly lose your life.
I would tell them to breathe. Knowledge is power and knowing is such a blessing. Many people will never know that
they will get cancer. This is such a blessing to those who can know and do something about it.
Don't start researching until you get your result, you will just freak your self out!
I would tell them that I know how nerve-wracking it can be to wait, and that the wait will be over soon! I'd
encourage them to do research if they are comfortable doing so, and consider the choices that they might make if
they test positive. I'd also encourage anyone who is considering testing or waiting for results to find a community of
people in the same boat - FORCE, Bright Pink's PinkPal program, Facebook groups like BRCA Sisterhood or
Young Previvors are all invaluable options!
That the mutation is not a death sentence, nor should it have a negative impact on your life. Knowing about the
mutation is knowledge, and knowledge is such a powerful thing. It gives us the power to prevent cancer before it
occurs, or at that very least significantly lower our risks. It allows us to be in control of our health, and life.
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Too not worry too much until you get the result back. Once you do have the results take your time before you do
anything and weigh all your options.
It's a blessing to know. You are the lucky ones who have precursors and you have the ability to set your future and
be proactive if you are positive
Relax. You tested for a reason. You must have a family history. Your surveillance will be high even if you are
negative. If you are positive. Welcome to the sisterhood, it won't always be easy, it won't always be cheap, and you
won't always understand it. But you are never along, you will din courage you never knew that you had. You will
have a chance to survive. My positive is a positive. I am positive and I know how to live the rest of my life now.
Try to keep your routine and carry on. You can't dwell on it, it is what it is, you were born with it and it has been
apart of you for X amount of years. Get educated and know your options and choices. FIND THE BEST
DOCTORS!!
No matter your result you are still you. Even if you end up positive you can still have a normal life.
To take things slowly and take time to process everything. To think about what you will do one way or another. But
not to freak out... Medicine is amazing and there are so many bugged things in life than BRCA.
It is normal to be concerned, worried and anxious to get results back. Bring someone to the appointment if you can
to help take notes or just to have a second set of ears, sometimes you don't remember everything when you are given
life altering news. Think about the different options prior to getting results back, but don't make any quick decisions
once you have been given positive results.
That knowledge is empowering, whatever that knowledge is it comes with choices that you can make. It's all about
what is right for you, so take it one-step and one day at a time and be grateful that you get to make a choice many
women are denied.
Listen to the opinions around you, but choose what makes you most comfortable in the end.
Although it seems like a negative thing or burden, these results do not determine your life. The results do not change
you, and thankfully to medical advancements there are precautionary steps to take. Do not let the result define you!
If you are positive, be thankful you were given the chance to know, and can take preventative measures! If you are
negative, still keep up on mammograms and self-checks, there is still family history! Live your life!
Just think positive and you will get through this.
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Appendix E: Additional Results
Satisfaction and Participant Worry. Each participant’s level of worry or concern
regarding finding a job, finding a place to live, completing school or duties at work,
finding a partner or getting married, having children or family planning, or reducing the
risk for cancer via surgeries, treatment, etc., was assessed. An ANOVA test was
preformed comparing each of these levels of worry or concern to the SWDS, and was not
found to be statistically significant. The p values ranged from p = 0.119 to p = 0.593.
Education vs. Life Planning and Age at Time of Study. Education level was
compared to the three life planning choice questions and age at the time of the study (See
Table 2.6). A significant association was found between participant education and if they
had received genetic counseling, χ2(4, N = 51) = 11.16, p = 0.03. Participants were more
likely to have had genetic counseling if they had reached a higher level in their education.
However, this test violated the rules of Chi-square test, since there were only four
participants total who did not have genetic counseling.
Income vs. Life Planning and Age at Time of Study. Most participants had a
personal income that was between $30,001 and $50,000 (37%) (see Table 2.7). No
significant relationships were found between participant income and life-planning
choices, or between participant ages at the time of the study.
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Table 2.11. Participant educational level vs. life planning choices or age at time of study.
Medical
management
plan in place
Education
Finished high school or GED
Some college education
Associate's degree
Bachelor's degree
College beyond a bachelor's
degree
Total
Chi-square

Yes
2
9
7
14

Family planning
or reproductive
options

Genetic
Counseling*

No
1
0
0
0

Yes
1
8
5
17

11
2
43
3
χ2(4, N = 47) =
4.72, p = 0.32

No
2
1
2
0

Yes
1
2
4
10

13
2
44
7
χ2(4, N = 51) =
11.16, p = 0.03*

No
2
7
3
6

6
9
23
27
χ2(4, N = 50) =
4.56, p = 0.34

Age at time of
study
Under
25 and
25
Over
2
1
5
4
3
4
5
12
4
10
19
31
χ2(4, N = 50) =
3.35, p = 0.50

Table 2.12. Personal income vs. life planning choices or age at time of study.
Medical
management plan in
place

Genetic Counseling

Family planning or
reproductive options

Personal income

Yes

No

Yes

No

Yes

No

Less than $12,000
$12,0001 to $30,000
$30,001 to $50,000
$50,001 to $100,000
More than $100,000

8
3
15
13
1

0
1
1
1
0

8
2
15
13
2

1
2
2
2
0

4
1
8
8
0

5
3
9
6
2

Total

40
3
χ2(4, N = 43) =
2.69, p = 6.11

Chi-square

40
7
χ2(4, N = 47) =
4.50, p = 0.34

Age at time of
study
Under
25 and
25
Over
6
2
6
2
0

21
25
χ2(4, N = 46) =
3.13, p = 0.54

3
2
10
13
2

16
30
χ2(4, N = 46) =
8.60, p = 0.72

Table 2.13. Participant ages by group vs. life planning choices.
Timeline for
Life

Overall Life
Plans

Medical
Management
Plan in Place

Genetic
Counseling

Age at time of
study

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No

Under 25

15

4

9

10

18

1

16

3

8

11

25 and Over
Total

20
35

11
15

14
23

17
27

26
44

5
6

27
43

4
7

14
22

16
27

ChiSquared/Fisher's
Exact Test

2

χ (1, N = 50) =
1.17, p = 0.23

2

χ (1, N = 50) =
0.02, p = 0.55
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2

χ (1, N = 50) =
1.32, p = 0.5

χ2(1, N =
50) = 0.08, p
= 0.54

Family Planning or
Reproductive
Options

χ2(1, N = 49) =
0.10, p = 0.49

Table 2.14. Participants who received genetic counseling vs. life planning.
Timeline for Life

Overall Life Plans

Genetic Counseling

Yes

No

Yes

No

Yes

33

12

23

22

No

5

3

1

7

38

15

24

29

Total
Chi-square/Fisher’s Exact Test

X2(1, N = 53) = 0.40, p = 0.40

X2(1, N = 53) = 4.09, p = 0.47

Life Stability and Genetic Testing Satisfaction. The number of years participants
were with their partners and the number of residency changes participants had in the past
eight years were asked to gauge life stability. These questions were compared to whether
or not participants felt that their positive BRCA1/2 mutation status affected their timeline
for life or their overall life plans. These questions were compared using an ANOVA test.
There was no significant effect between years with partner and timeline for life, F(1, 32)
= 0.89, p = 0.35. There was no significant difference between the number of years with
partner and overall life plan, F(1, 32) = 0.46, p = 0.50. There was no significant
difference between number of residency changes an timeline for life, F(1, 34) = 0.16, p =
0.70. No significant difference between number of residency changes and overall life
plan was found, F(1, 34) = 0.01, p = 0.92.
Genetic testing results disclosure. Participants were informed of their positive
genetic test result in clinic (n = 26) or outside of clinic (n = 27). The number of times
participants reported specific details about their experience were counted (Table 2.15).
A main theme among responses by participants who received their result while
outside of clinic was recalling what they were doing or where they were at the time of
results disclosure (n = 23). Most participants who received their result outside of clinic
were at home when they received the call (n = 12) and were called by a genetic counselor
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(n = 8). Most of the participants who received their test result in clinic also spoke to a
genetic counselor (n = 16) and brought along family members or a significant other (7).
One participant, who relived her result outside of clinic, wrote “I originally asked
for my results by letter but when it came down to knowing the answer, I decided to rip it
off like a Band-Aid and find out. I was at work and I got a call from my genetic
counselor (on my cell).” Another wrote, “I was at work when I received the call. It was
upsetting to find out but I knew I was at risk because of my family history.”
Table 2.15. Genetic testing results disclosure.
Genetic Testing Results Disclosure (n = 61)
Outside of clinic
Cited specific details about the moment of results disclosure
At home
At work
In the car
At lunch
At college
Cell phone
Over the phone
Called by a genetic counselor
Sought support from family/significant other after the news
Expressed that they were upset by the result
Called by doctor
Follow up appointment with a doctor
Previously devised a plan for results disclosure with a provider
Follow up appointment with a genetic counselor
Expressed that they were happy to know their result
Land line phone
Posted while on nursing placement
Over Skype by mother - while in Japan
In clinic
Genetic counselor
Came to appointment with family or significant other
Doctor
Letter in the mail
Oncologist
Oncologist and genetic counselor
Geneticist
Follow up appointment with a genetic counselor
Not surprised when informed of result
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n
27
23
12
5
3
2
1
14
10
8
8
6
4
4
2
2
2
1
1
1
26
16
7
5
3
2
1
1
1
8

One of the participants who came to clinic with her family members
wrote: Once my mum was confirmed BRCA [mutation carrier] the
females in my family were given the option to be tested. We did this
altogether and so we all went to the hospital as a family to get our
results… my auntie and myself were positive and my sister was negative.
It was strange: my sister was upset for me, I was upset for my auntie and
my mum was just devastated and pleased at the same time…. Pleased for
my sister by devastated for me and my auntie and we were all sad that
they didn’t know about this and we could have perhaps saved my
grandma.
Another who was not surprised by her result wrote, “In my heart I knew I was
positive. I was prepared. He [the geneticist] was most shocked when I thanked him. He
was concerned as at the time I was the youngest person he had to give results to in the
clinical [HBOC] study.”
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